UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2025~~2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ______________

Commission File Number: 001-41695

CORE LABORATORIES INC.

(Exact name of registrant as specified in its charter)


Delaware		98-1164194
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

6316 Windfern Road
Houston, TX		77040
(Address of principal executive offices)		(Zip Code)

(713) 328-2673

(Registrant's telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

     Title of each class

     Trading
Symbol(s)

     Name of each exchange on which registered

     Common Stock (par value $0.01)

     CLB

     New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☒	Accelerated filer ☐	Non-accelerated filer ☐	Smaller reporting company ☐	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of common stock of the registrant, par value $0.01 per share, outstanding at ~~October~~April 1724, ~~2025~~2026 was 46,~~563~~096,~~387~~682.

CORE LABORATORIES INC.

FORM 10-Q FOR THE QUARTER ENDED ~~SEPTEMBER~~MARCH 3031, ~~2025~~2026

INDEX

PART I - FINANCIAL INFORMATION

		Page
Item 1.	Financial Statements
	Consolidated Balance Sheets at September 30, 2025 (Unaudited) and December 31, 2024	3
	Consolidated Balance Sheets at March 31, 2026 (Unaudited) and December 31, 2025	3
	Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)	4
	Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (Unaudited)	4
	Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)	6
	Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended March 31, 2026 and 2025 (Unaudited)	5
	Consolidated Statements of Changes in Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited)	7
	Consolidated Statements of Changes in Equity for the Three Months Ended March 31, 2026 and 2025 (Unaudited)	6
	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited)	9
	Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)	8
	Notes to the Interim Consolidated Financial Statements (Unaudited)	109
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2119
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3530
Item 4.	Controls and Procedures	3530
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	3531
Item 1A.	Risk Factors	3531
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3631
Item 5.	Other Information	3731
Item 6.	Exhibits	3832
	Signature	3933

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

CORE LABORATORIES INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

	September 30,2025			December 31,2024
	March 31,2026			December 31,2025
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	2522,~~629~~819		$	1922,~~157~~702
Accounts receivable, net of allowance for credit losses of $5,296 and $3,192 at 2025 and 2024, respectively		110,258			111,761
Accounts receivable, net of allowance for credit losses of $6,488 and $6,317 at 2026 and 2025, respectively		108,277			113,528
Inventories		5857,~~241~~784			5954,~~402~~496
Prepaid expenses		1011,~~056~~356			109,~~176~~734
Income taxes receivable		146,~~716~~917			157,~~594~~270
Other current assets		87,~~014~~218			106,~~516~~935
TOTAL CURRENT ASSETS		~~226~~214,~~914~~371			~~226~~214,~~606~~665
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $321,113 and $314,317 at 2025 and 2024, respectively		98,031			97,063
PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $319,112 and $320,707 at 2026 and 2025, respectively		99,985			99,447
RIGHT OF USE ASSETS		5354,~~980~~708			5654,~~488~~346
INTANGIBLES, net of accumulated amortization and impairment of $19,470 and $19,326 at 2025 and 2024, respectively		6,107			6,403
INTANGIBLES, net of accumulated amortization and impairment of $19,739 and $19,531 at 2026 and 2025, respectively		6,893			7,118
GOODWILL		~~100~~105,~~012~~796			99105,~~445~~789
DEFERRED TAX ASSETS, net		7071,~~506~~296			6967,~~613~~381
OTHER ASSETS		3534,~~810~~679			3435,~~788~~264
TOTAL ASSETS	$	~~591~~587,~~360~~728		$	~~590~~584,~~406~~010
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	3639,~~945~~982		$	3437,~~549~~275
Accrued payroll and related costs		2322,~~363~~295			2226,~~901~~525
Taxes other than payroll and income		34,~~852~~065			74,~~106~~272
Unearned revenues		74,~~258~~708			95,~~332~~552
Operating lease liabilities		1112,~~474~~097			1011,~~690~~456
Income taxes payable		34,~~513~~214			4,~~851~~255
Other current liabilities		917,~~338~~373			816,~~157~~680
TOTAL CURRENT LIABILITIES		95104,~~743~~734			97106,~~586~~015
LONG-TERM DEBT, net		114,~~103~~460			~~126~~110,~~111~~255
LONG-TERM OPERATING LEASE LIABILITIES		41,~~525~~285			4342,~~343~~309
DEFERRED COMPENSATION		3128,~~054~~165			3129,~~115~~381
DEFERRED TAX LIABILITIES, net		108,~~102~~073			137,~~783~~995
OTHER LONG-TERM LIABILITIES		2115,~~445~~867			2015,~~732~~847
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding		—			—
Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 46,086,944 outstanding at 2025; 46,966,868 issued and 46,826,820 outstanding at 2024		470			470
Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 46,048,268 outstanding at 2026; 46,966,868 issued and 46,095,379 outstanding at 2025		470			470
Additional paid-in capital		~~113~~115,~~874~~221			~~109~~110,~~547~~245
Retained earnings		~~173~~171,~~598~~413			~~150~~172,~~280~~662
Accumulated other comprehensive income (loss)		(5,~~984~~754	)		(5,~~769~~806	)
Treasury stock (at cost), 879,924 and 140,048 shares at 2025 and 2024, respectively		(10,611	)		(2,537	)
Treasury stock (at cost), 918,600 and 871,489 shares at 2026 and 2025, respectively		(12,464	)		(11,585	)
Total Core Laboratories Inc. shareholders' equity		~~271~~268,~~347~~886			~~251~~265,~~991~~986
Non-controlling interest		6,~~041~~258			56,~~745~~222
TOTAL EQUITY		~~277~~275,~~388~~144			~~257~~272,~~736~~208
TOTAL LIABILITIES AND EQUITY	$	~~591~~587,~~360~~728		$	~~590~~584,~~406~~010

The accompanying notes are an integral part of these interim consolidated financial statements.

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Three Months Ended
	September 30,
	March 31,
	2025			2024
	2026			2025
	(Unaudited)
REVENUE:
Services	$	~~101~~94,~~125~~252		$	9895,~~842~~091
Product sales		3327,~~396~~545			3528,~~555~~494
Total revenue		~~134~~121,~~521~~797			~~134~~123,~~397~~585
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below		7476,~~896~~115			7572,~~503~~980
Cost of product sales, exclusive of depreciation expense shown below		3025,~~005~~958			3126,~~302~~489
General and administrative expense, exclusive of depreciation expense shown below		1014,~~688~~718			813,~~642~~647
Depreciation		3,~~529~~556			3,~~551~~593
Amortization		65208			~~125~~124
Other (income) expense, net		(~~5,590~~645	)		(42,~~529~~335	)
OPERATING INCOME		201,~~928~~887			194,~~803~~417
Interest expense		2,~~650~~891			32,~~108~~602
Income before income taxes		18,278			16,695
Income (loss) before income taxes		(1,004	)		1,815
Income tax expense		3,754			4,691
Income tax expense (benefit)		(251	)		1,746
Net income		14,524			12,004
Net income (loss)		(753	)		69
Net income attributable to non-controlling interest		~~285~~36			~~259~~223
Net income attributable to Core Laboratories Inc.	$	14,239		$	11,745
Net income (loss) attributable to Core Laboratories Inc.	$	(789	)	$	(154	)
EARNINGS PER SHARE INFORMATION:
Basic earnings per share	$	0.31		$	0.26
Basic earnings (loss) per share	$	(0.02	)	$	—
Basic earnings per share attributable to Core Laboratories Inc.	$	0.31		$	0.25
Basic earnings (loss) per share attributable to Core Laboratories Inc.	$	(0.02	)	$	—
Diluted earnings per share	$	0.31		$	0.25
Diluted earnings (loss) per share	$	(0.02	)	$	—
Diluted earnings per share attributable to Core Laboratories Inc.	$	0.30		$	0.25
Diluted earnings (loss) per share attributable to Core Laboratories Inc.	$	(0.02	)	$	—
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic		46,~~263~~073			46,~~922~~773
Diluted		47,078			47,820
Assuming dilution		46,073			46,773

The accompanying notes are an integral part of these interim consolidated financial statements.

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF ~~OPERATIONS~~COMPREHENSIVE INCOME (LOSS)

(In thousands~~, except per share data~~)

	Nine Months Ended
	Three Months Ended
	September 30,
	March 31,
	2025			2024
	2026			2025
	(Unaudited)
REVENUE:
Net income (loss)	$	(753	)	$	69
Services	$	292,435		$	291,674
Other comprehensive income (loss):
Product sales		95,830			102,937
Interest rate swaps:
Total revenue		388,265			394,611
Interest rate swap amount reclassified to net income		(6	)		(220	)
OPERATING EXPENSES:
Income tax benefit on interest rate swaps reclassified to net income		1			46
Cost of services, exclusive of depreciation expense shown below		221,929			224,191
Total interest rate swaps		(5	)		(174	)
Cost of product sales, exclusive of depreciation expense shown below		86,142			90,132
Pension and other postretirement benefit plans:
General and administrative expense, exclusive of depreciation expense shown below		34,799			30,690
Amortization of actuarial gain reclassified to net income		77			77
Depreciation		10,683			10,909
Income tax expense on pension and other postretirement benefit plans reclassified to net income		(20	)		(20	)
Amortization		298			380
Total pension and other postretirement benefit plans		57			57
Other (income) expense, net		(6,222	)		(6,073	)
Total other comprehensive income (loss)		52			(117	)
OPERATING INCOME		40,636			44,382
Comprehensive loss		(701	)		(48	)
Interest expense		7,963			9,740
Comprehensive income attributable to non-controlling interest		36			223
Income before income taxes		32,673			34,642
Comprehensive loss attributable to Core Laboratories Inc.	$	(737	)	$	(271	)
Income tax expense		7,411			9,958
Net income		25,262			24,684
Net income attributable to non-controlling interest		541			687
Net income attributable to Core Laboratories Inc.	$	24,721		$	23,997
EARNINGS PER SHARE INFORMATION:
Basic earnings per share	$	0.54		$	0.53
Basic earnings per share attributable to Core Laboratories Inc.	$	0.53		$	0.51
Diluted earnings per share	$	0.53		$	0.52
Diluted earnings per share attributable to Core Laboratories Inc.	$	0.52		$	0.50
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic		46,552			46,897
Diluted		47,381			47,690

The accompanying notes are an integral part of these interim consolidated financial statements.

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2025			2024			2025			2024
	(Unaudited)
Net income	$	14,524		$	12,004		$	25,262		$	24,684
Other comprehensive income (loss):
Interest rate swaps:
Interest rate swap amount reclassified to net income		(108	)		(235	)		(489	)		(780	)
Income tax benefit on interest rate swaps reclassified to net income		24			50			103			164
Total interest rate swaps		(84	)		(185	)		(386	)		(616	)
Pension and other postretirement benefit plans:
Amortization of actuarial gain reclassified to net income		77			63			232			191
Income tax expense on pension and other postretirement benefit plans reclassified to net income		(20	)		(15	)		(61	)		(49	)
Total pension and other postretirement benefit plans		57			48			171			142
Total other comprehensive income (loss)		(27	)		(137	)		(215	)		(474	)
Comprehensive income		14,497			11,867			25,047			24,210
Comprehensive income attributable to non-controlling interest		285			259			541			687
Comprehensive income attributable to Core Laboratories Inc.	$	14,212		$	11,608		$	24,506		$	23,523

The accompanying notes are an integral part of these interim consolidated financial statements.

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(In thousands, except share and per share data)

	Three Months Ended						~~Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2025			2024			2025			2024
	2026			2025
	(Unaudited)
Common Stock
Balance at Beginning of Period	$	470		$	~~469~~470		$	~~470~~		$	~~469~~
Balance at End of Period	$	470		$	~~469~~470		$	~~470~~		$	~~469~~
Additional Paid-In Capital
Balance at Beginning of Period	$	~~112~~110,~~763~~245		$	~~113~~109,~~479~~547		$	~~109,547~~		$	~~110,011~~
Stock-based compensation		14,~~111~~976			~~(869~~4,027	)		~~4,327~~			~~2,599~~
Balance at End of Period	$	~~113~~115,~~874~~221		$	~~112~~113,~~610~~574		$	~~113,874~~		$	~~112,610~~
Retained Earnings
Balance at Beginning of Period	$	~~159~~172,~~824~~662		$	~~132~~144,~~070~~862		$	~~150,280~~		$	~~120,756~~
Dividends paid		(~~465~~460	)		(469	)		~~(1,403~~	)		~~(1,407~~	)
Net income attributable to Core Laboratories Inc.		14,239			11,745			24,721			23,997
Net income (loss) attributable to Core Laboratories Inc.		(789	)		(154	)
Balance at End of Period	$	~~173~~171,~~598~~413		$	~~143~~144,~~346~~239		$	~~173,598~~		$	~~143,346~~
Accumulated Other Comprehensive Income (Loss)
Balance at Beginning of Period	$	(5,~~957~~806	)	$	(5,~~309~~769	)	$	~~(5,769~~	)	$	~~(4,972~~	)
Interest rate swaps, net of income taxes		(845	)		(~~185~~174	)		~~(386~~	)		~~(616~~	)
Pension and other postretirement benefit plans, net of income taxes		57			4857			~~171~~			~~142~~
Balance at End of Period	$	(5,~~984~~754	)	$	(5,~~446~~886	)	$	~~(5,984~~	)	$	~~(5,446~~	)
Treasury Stock
Balance at Beginning of Period	$	(511,~~817~~585	)	$	(~~435~~2,537	)	$	~~(2,537~~	)	$	~~(1,449~~	)
Stock-based compensation		~~215~~56			~~394~~132			~~1,696~~			~~1,614~~
Repurchase of common stock		(~~5,009~~935	)		(~~196~~2,022	)		~~(9,770~~	)		~~(402~~	)
Balance at End of Period	$	(1012,~~611~~464	)	$	(~~237~~4,427	)	$	~~(10,611~~	)	$	~~(237~~	)
Non-Controlling Interest
Balance at Beginning of Period	$	6,~~020~~222		$	5,~~420~~745		$	~~5,745~~		$	~~4,992~~
Non-controlling interest contribution		—			—			19			—
Net income attributable to non-controlling interest		36			223
Non-controlling interest dividend		(264	)		—			(264	)		—
Balance at End of Period	$	6,258		$	5,968
Net income attributable to non-controlling interest		285			259			541			687
Total Equity
Balance at End of Period	$	6,041		$	5,679		$	6,041		$	5,679
Balance at Beginning of Period	$	272,208		$	252,318
Total Equity
Stock-based compensation		5,032			4,159
Balance at Beginning of Period	$	267,303		$	245,694		$	257,736		$	229,807
Dividends paid		(460	)		(469	)
Stock-based compensation		1,326			(475	)		6,023			4,213
Net income (loss)		(753	)		69
Non-controlling interest contribution		—			—			19			—
Interest rate swaps, net of income taxes		(5	)		(174	)
Non-controlling interest dividend		(264	)		—			(264	)		—
Pension and other postretirement benefit plans, net of income taxes		57			57
Dividends paid		(465	)		(469	)		(1,403	)		(1,407	)
Repurchase of common stock		(935	)		(2,022	)
Net income		14,524			12,004			25,262			24,684
Balance at End of Period	$	275,144		$	253,938
Interest rate swaps, net of income taxes		(84	)		(185	)		(386	)		(616	)
Cash Dividends per Share	$	0.01		$	0.01
Pension and other postretirement benefit plans, net of income taxes		57			48			171			142
Repurchase of common stock		(5,009	)		(196	)		(9,770	)		(402	)
Balance at End of Period	$	277,388		$	256,421		$	277,388		$	256,421
Cash Dividends per Share	$	0.01		$	0.01		$	0.03		$	0.03

The accompanying notes are an integral part of these interim consolidated financial statements.

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Continued)

(In thousands, except share and per share data)

Three Months Ended

~~Nine Months Ended~~

September 30,

March 31,

2025

2024

2025

2024

2026

2025

(Unaudited)

Common Stock - Number of shares issued

Balance at Beginning of Period

46,966,868

46,~~938~~966,~~557~~868

~~46,966,868~~

~~46,938,557~~

Balance at End of Period

46,966,868

46,~~938~~966,~~557~~868

~~46,966,868~~

~~46,938,557~~

Treasury Stock - Number of shares

Balance at Beginning of Period

(~~430~~871,~~078~~489

)

(25140,~~862~~048

)

~~(140,048~~

)

~~(82,021~~

)

Stock-based compensation

124,~~402~~670

236,~~242~~970

~~91,602~~

~~92,313~~

Repurchase of common stock

(~~462~~51,~~248~~781

)

(8131,~~546~~598

)

~~(831,478~~

)

~~(21,458~~

)

Balance at End of Period

(~~879~~918,~~924~~600

)

(11264,~~166~~676

)

~~(879,924~~

)

~~(11,166~~

)

Common Stock - Number of shares outstanding

Balance at Beginning of Period

46,~~536~~095,~~790~~379

46,~~912~~826,~~695~~820

~~46,826,820~~

~~46,856,536~~

Stock-based compensation

124,~~402~~670

236,~~242~~970

~~91,602~~

~~92,313~~

Repurchase of common stock

(~~462~~51,~~248~~781

)

(8131,~~546~~598

)

~~(831,478~~

)

~~(21,458~~

)

Balance at End of Period

46,~~086~~048,~~944~~268

46,~~927~~702,~~391~~192

~~46,086,944~~

~~46,927,391~~

The accompanying notes are an integral part of these interim consolidated financial statements.

Return to Index

CORE LABORATORIES INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Nine Months Ended
	Three Months Ended
	September 30,
	March 31,
	2025			2024
	2026			2025
	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	25,262		$	24,684
Net income (loss)	$	(753	)	$	69
Adjustments to reconcile net income to net cash provided by operating activities:
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Stock-based compensation		65,~~023~~032			4,~~213~~159
Depreciation and amortization		103,~~981~~764			113,~~289~~717
Assets write-down		34180			~~1,110~~34
Inventory write-off and obsolescence		~~2,429~~168			~~1,015~~643
Provision for credit losses		2,152			1,222
Net provision for credit losses		241			668
Changes in value of life insurance policies		~~(1,851~~513	)		~~(3,188~~779	)
Deferred income taxes		(43,~~573~~719	)		~~102~~(1,817	)
Insurance recovery on property, plant and equipment		(6,830	)		(2,102	)
Realization of pension obligation		47			45
Other non-cash items		~~852~~(730	)		~~256~~872
Changes in assets and liabilities:
Accounts receivable		~~(615~~5,010	)		(96,~~461~~606	)
Inventories		(13,~~268~~456	)		~~5,197~~(272	)
Prepaid expenses and other current assets		(~~797~~1,551	)		(41,~~357~~391	)
Other assets		(~~351~~7	)		~~(205~~3	)
Accounts payable		12,~~284~~847			~~(373~~2,971	)
Accrued expenses		(~~3,370~~845	)		~~2,392~~617
Unearned revenues		(~~2,074~~844	)		~~2,453~~440
Other liabilities		(1,~~797~~932	)		(1,~~526~~053	)
Net cash provided by operating activities		293,~~085~~965			356,~~773~~660
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures - operations		(83,~~265~~448	)		(82,~~647~~785	)
Capital expenditures - rebuilding of Aberdeen facility		(21,~~672~~443	)		—(794	)
Proceeds from insurance recovery - Aberdeen facility		~~9,951~~—			23,~~102~~121
Patents and other intangibles		(2	)		—
Proceeds from sale of assets		1,491			1,230
Acquisitions, net of cash acquired		(617	)		—
Patents and other intangibles		9			—
Proceeds from sale of assets		2,348			934
Net cash provided by (used in) investing activities		(3,391	)		772
Net proceeds on life insurance policies		778			2,776
Net cash provided by (used in) investing activities		1,521			(2,835	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of long-term debt		(4762,000	)		(6215,000	)
Proceeds from long-term debt		3666,000			3813,000
Debt issuance costs		(1,706	)		—
Dividends paid		(460	)		(469	)
Dividends paid		(1,403	)		(1,407	)
Repurchase of common stock		(3,997	)		(2,022	)
Repurchase of common stock		(9,770	)		(402	)
Other financing activities		—			9
Equity related transaction costs		—			(756	)
Net cash used in financing activities		(457	)		(4,482	)
Other financing activity		(255	)		(19	)
NET CHANGE IN CASH AND CASH EQUIVALENTS		117			2,950
Net cash used in financing activities		(24,134	)		(26,584	)
CASH AND CASH EQUIVALENTS, beginning of period		22,702			19,157
NET CHANGE IN CASH AND CASH EQUIVALENTS		6,472			6,354
CASH AND CASH EQUIVALENTS, end of period	$	22,819		$	22,107
CASH AND CASH EQUIVALENTS, beginning of period		19,157			15,120
CASH AND CASH EQUIVALENTS, end of period	$	25,629		$	21,474
Supplemental disclosures of cash flow information:
Cash payments for interest	$	62,~~553~~875		$	82,~~741~~260
Cash payments for income taxes	$	9,535		$	11,892
Cash payments (net of refunds) for income taxes	$	2,971		$	1,015
Non-cash investing and financing activities:
Capital expenditures incurred but not paid for as of the end of the period	$	1,~~006~~482		$	1,~~591~~990

The accompanying notes are an integral part of these interim consolidated financial statements.

Return to Index

CORE LABORATORIES INC.

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. DESCRIPTION OF BUSINESS

References to “Core Lab”, “Core Laboratories”, the “Company”, “we”, “our” and similar phrases are used throughout this Quarterly Report on Form 10-Q (“Quarterly Report”) and relate collectively to Core Laboratories Inc. and its consolidated subsidiaries.

We operate our business in two segments: (1) Reservoir Description and (2) Production Enhancement. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields. For a description of the types of services and products offered by these operating segments, see Note 1615 - Segment Reporting.

2. SIGNIFICANT ACCOUNTING POLICIES UPDATE

Basis of Presentation and Principles of Consolidation

The accompanying unaudited interim consolidated financial statements include the accounts of Core Laboratories Inc. and its subsidiaries for which we have a controlling voting interest and/or a controlling financial interest. These financial statements have been prepared in accordance with United States ~~Generally~~generally ~~Accepted~~accepted ~~Accounting~~accounting ~~Principles~~principles (“U.S. GAAP”) for interim financial information using the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information and footnote disclosures required by U.S. GAAP for the annual financial statements and should be read in conjunction with the audited financial statements and notes thereto included in Core Laboratories Inc.’s Annual Report on Form 10-K for the year ended December 31, ~~2024~~2025, including Note 2 - Summary of Significant Accounting Policies. Core Laboratories Inc.’s balance sheet information for the year ended December 31, ~~2024~~2025, was derived from the ~~2024~~2025 audited consolidated financial statements. There have been no changes to the accounting policies during the ~~nine~~three months ended ~~September~~March 3031, ~~2025~~2026, except as noted below.

Core Laboratories Inc. uses the equity method of accounting for investments in which it has less than a majority interest and does not exercise control but does exert significant influence. Non-controlling ~~interests~~interest ~~have~~has been recorded to reflect outside ownership attributable to consolidated subsidiaries that are less than 100% owned. All inter-company transactions and balances have been eliminated in consolidation.

In the opinion of management, all adjustments considered necessary for a fair statement of the results for the interim periods presented have been included in these financial statements. Furthermore, the operating results presented for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~2026, may not necessarily be indicative of the results that may be expected for the year ending December 31, ~~2025~~2026.

Certain reclassifications were made to prior period amounts included in this Quarterly Report on Form 10-Q in order to conform to the current period presentations. Refer to Core Laboratories Inc.’s Annual Report on Form 10-K for the year ended December 31, 2025, Note 2 - Summary of Significant Accounting Policies - Prior Period Immaterial Corrections. Specifically, the Company has made adjustments to previously reported beginning retained earnings and total assets for the three months ended March 31, 2025. These reclassifications had no impact on the reported net income or cash flows for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024~~2025.

Property, Plant and Equipment

We review our long-lived assets (“LLA”) for impairment when events or changes in circumstances indicate that their net book value may not be recovered over their remaining service lives. Indicators of possible impairment may include significant declines in activity levels in regions where specific assets or groups of assets are located, extended periods of idle use, declining revenue or cash flow or overall changes in general market conditions.

The geopolitical conflict between Russia and Ukraine, which began in February 2022 and has continued through September 30, 2025, has resulted in disruptions to our operations in Russia and Ukraine. As of September 30, 2025, our 9

Return to Index

~~laboratory~~We ~~facilities,~~have ~~offices,~~performed ~~and~~assessments ~~locations~~for inLLA ~~Russia~~located ~~and~~in ~~Ukraine~~regions ~~continued~~impacted toby ~~operate~~the ~~with~~Middle noEast ~~significant~~and ~~impact~~Russia/Ukraine togeopolitical ~~local~~conflicts ~~business~~and ~~operations. Therefore, we determined there was~~ no triggering ~~event~~events ~~for~~have ~~LLA~~been ~~impairment~~identified into ~~Russia~~indicate ~~and~~that ~~Ukraine,~~their ~~and~~net nobook ~~impairment~~value ~~assessments~~may ~~have~~not ~~been~~be ~~performed~~recoverable as of ~~September~~March 3031, ~~2025~~2026.

Recent Accounting Pronouncements

Pronouncements Adopted in 2026

In July 2025, FASB issued ASU 2025-05 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which allows public business entities to apply a practical expedient when estimating expected credit losses that assumes that current conditions as of the balance sheet date do not change for the remaining life of the asset. The amendment is effective for annual and interim periods beginning after December 15, 2025. We adopted the guidance during the three months ended March 31, 2026. The Company has elected to apply the practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. When an account is determined to be uncollectible, we charge the receivable to our allowance for credit losses.

Issued But Not Yet Effective

In December 2023, FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures to improve transparency of income tax disclosures, primarily by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The amendment is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The amendment should be applied prospectively; however, retrospective application is permitted. Upon adoption, our disclosures regarding income taxes will be expanded accordingly.

In November 2024, FASB issued ASU 2024-03 Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40) to improve disclosures about a public business entity’s expenses, by providing more detailed information about the types of expenses in commonly presented expense captions. As amended by ASU 2025-01 issued in January 2025, the amendment is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendment may be applied prospectively or retrospectively. Upon adoption, our disclosures regarding expenses will be expanded.

In ~~July~~December 2025, FASB issued ASU 2025-~~05 Financial Instruments~~11—~~Credit~~Interim ~~Losses~~Reporting (Topic ~~326~~270): ~~Measurement~~Narrow-Scope Improvements to clarify the applicability of ~~Credit~~Topic ~~Losses~~270, ~~for~~including ~~Accounts~~types ~~Receivable~~of interim reporting and ~~Contract~~the ~~Assets,~~form ~~which~~and ~~allows~~content ~~public~~of ~~business~~interim ~~entities~~financial tostatements. ~~apply~~It also provides a ~~practical~~comprehensive ~~expedient~~list ~~when~~of ~~estimating~~required ~~expected~~interim ~~credit~~disclosures ~~losses~~and ~~that~~requires ~~assumes~~entities ~~that~~to ~~current~~disclose ~~conditions~~events assince the end of the ~~balance~~last ~~sheet~~annual ~~date~~reporting doperiod ~~not~~that ~~change~~have ~~for~~a ~~the~~material ~~remaining~~impact ~~life~~on of the ~~asset~~entity. The amendment is effective for ~~annual~~interim ~~and~~periods ~~interim~~within annual reporting periods beginning after December 15, ~~2025~~2027. Early adoption is permitted. ~~The~~We ~~amendment~~do ~~will~~not beexpect ~~applied~~the ~~prospectively.~~update ~~Upon~~to ~~adoption,~~have ~~our~~an ~~disclosures~~effect ~~regarding~~on ~~estimating~~our ~~expected~~interim ~~credit losses will be expanded~~reporting.

3. ACQUISITIONS AND ~~DIVESTURES~~DIVESTITURES

We had no significant business acquisitions or ~~divestures~~divestitures during the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~2026 and ~~2024~~2025.

~~Subsequent to the quarter ending September 30, 2025, on October 1, 2025, we acquired 100% of the equity interests in Solintec Consultoria E Servicos De Geologia Ltda~~4., ~~a Brazilian limited liability company and a leading provider of geological services to the region’s oil and gas industry. The acquisition is included in our Reservoir Description operating segment.~~INVENTORIES

The total purchase price is comprised of an initial cash payment of $2.3 million plus up to $3.7 million of additional contingent cash consideration, payable in annual installments, provided certain performance targets are achieved over the two-year period following closing.

We have not finalized the assessment of the fair values of assets acquired, including intangible assets, and liabilities assumed or the resulting goodwill and its taxability. Fair value estimates of certain assets and liabilities require more current financial information or are based on significant judgments and assumptions. Our estimates of acquisition date fair value will be adjusted where required as additional information is received during the measurement period subsequent to the acquisition date, not to exceed one year.

4. CONTRACT ASSETS AND LIABILITIES

The balance of contract assets and liabilities consisted of the following (in thousands):

Return to Index

	September 30,2025		December 31,2024
Contract assets:
Current	$	1,162	$	370
	$	1,162	$	370
Contract liabilities:
Current	$	426	$	560
	$	426	$	560

	September 30,2025
Estimate of when contract liabilities will be recognized as revenue:
Within 12 months	$	426

The current portion of contract assets is included in our accounts receivable. The current portion of contract liabilities is included in unearned revenues and, as applicable, the non-current portion of contract liabilities is included in other long-term liabilities.

We did not recognize any impairment losses on our contract assets during the three and nine months ended September 30, 2025 and 2024.

5. INVENTORIES

Inventories consist of the following (in thousands):

	September 30,2025		December 31,2024
	March 31,2026		December 31,2025
Finished goods	$	2827,~~940~~201	$	2724,~~127~~962
Parts and materials		2627,~~525~~752		2826,~~953~~932
Work in progress		2,~~776~~831		32,~~322~~602
Total inventories	$	5857,~~241~~784	$	5954,~~402~~496

We include freight costs incurred for shipping inventory to our clients in the cost of product sales caption in the accompanying consolidated statements of operations.

~~6. LEASES~~10

We have operating leases primarily consisting of office and lab space, machinery and equipment and vehicles. We entered into a sublease agreement in 2023 that was terminated at the beginning of 2025, for existing office and lab space in Calgary, Alberta, Canada.

Return to Index

5. LEASES

Our operating leases primarily consist of offices and lab space, machinery, equipment, and vehicles. We terminated certain leases in the U.S. and other international locations during the three months ending March 31, 2026 and 2025. See Note 12 - Other (Income) Expense, net for additional information regarding lease termination costs.

The components of lease expense and other information are as follows (in thousands):

	Three Months Ended						~~Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2025			2024			2025			2024
	2026			2025
Consolidated Statements of Operations:
Operating lease expense	$	4,~~243~~475		$	4,~~296~~178		$	~~12,589~~		$	~~12,942~~
Short-term lease expense		~~453~~411			~~393~~489			~~1,334~~			~~1,230~~
Variable lease expense		~~425~~479			~~212~~481			~~1,284~~			~~1,032~~
Sublease income		—			(56	)		—			(169	)
Total lease expense	$	5,365		$	5,148
Total lease expense	$	5,121		$	4,845		$	15,207		$	15,035
Consolidated Statements of Cash Flows:
Consolidated Statements of Cash Flows:
Operating cash flows - operating leases payments	$	4,431		$	4,206
Operating cash flows - operating leases payments	$	3,927		$	3,882		$	12,822		$	12,791
Right of use assets obtained in exchange foroperating lease liabilities	$	4,354		$	4,155
Right of use assets obtained (released) in exchange foroperating lease obligations	$	2,184		$	3,647		$	7,060		$	10,606
Other information:
Other information:
Weighted-average remaining lease term - operating leases	7.72 years			8.38 years
Weighted-average remaining lease term - operating leases	8.19 years			8.40 years			8.19 years			8.40 years
Weighted-average discount rate - operating leases		5.42	%		5.46	%
Weighted-average discount rate - operating leases		5.48	%		5.41	%		5.48	%		5.41	%

Scheduled undiscounted lease payments for non-cancellable operating leases consist of the following (in thousands):

	September 30, 2025
	March 31, 2026
	Operating Leases
Remainder of 2025	$	3,786
Remainder of 2026	$	12,703
2026		12,927
2027		11,257
2027		10,140
2028		8,810
2028		7,903
2029		6,145
2029		5,330
2030		4,320
Thereafter		2622,~~146~~904
Total undiscounted lease payments		66,~~232~~139
Less: Imputed interest		(1312,~~233~~757	)
Total operating lease liabilities	$	5253,~~999~~382

76. LONG-TERM DEBT, NET

We have no finance lease obligations. Debt is summarized in the following table (in thousands):

	Interest Rate	Maturity Date	~~September~~March 3031,~~2025~~2026			December 31,~~2024~~2025
Credit Facility			$	7,000		$	18,000
Credit Facility - Revolving Loan	Variable	July 22, 2029	$	2,000		$	3,000
2021 Senior Notes Series A (1)	4.09%	January 12, 2026		45,000			45,000
Credit Facility - Delayed Draw Term Loan	Variable	July 22, 2029		50,000			—
2021 Senior Notes Series A (1)	4.09%	January 12, 2026		—			45,000
2021 Senior Notes Series B (1)	4.38%	January 12, 2028		15,000			15,000
2023 Senior Notes Series A (2)	7.25%	June 28, 2028		25,000			25,000
2023 Senior Notes Series B (2)	7.50%	June 28, 2030		25,000			25,000
Total long-term debt				117,000			~~128~~113,000
Less: Debt issuance costs				(2,~~897~~540	)		(12,~~889~~745	)
Long-term debt, net			$	114,~~103~~460		$	~~126~~110,~~111~~255

(1) Interest is payable semi-annually on June 30 and December 30.

~~(2) Interest is payable semi-annually on March 28 and September 28.~~11

Return to Index

~~through~~(2) ~~January~~Interest ~~12, 2026. The DDTL~~ is ~~repayable~~payable insemi-annually ~~quarterly~~on ~~installments~~March of28 ~~$625 thousand~~ and ~~prepayments~~September ~~are permitted without penalty~~28. Any remaining outstanding balances under the revolving credit facility and the DDTL are due at maturity on July 22, 2029, subject to springing maturity dates unless the Company’s liquidity equals or exceeds the principal amount of each of the respective senior notes series that remain outstanding on each of the respective springing maturity dates as follows:

On July 22, 2025, we, along with our direct subsidiary Core Laboratories (U.S.) Interests Holdings, Inc. (“CLIH”) entered into the Ninth Amended and Restated Credit Agreement (as amended, the “Credit Facility”) for an aggregate borrowing commitment of $150.0 million with a $50.0 million “accordion” feature. Draws up to $100.0 million are available in the form of a revolving credit facility, and a single draw of $50.0 million was made in the form of a delayed draw term loan (“DDTL”) on January 12, 2026. The $50.0 million proceeds from the DDTL were primarily used to retire $45.0 million of Senior Notes Series A, which matured on January 12, 2026, see further discussion below. The DDTL is repayable in quarterly installments of $625 thousand beginning June 2026, and prepayments are permitted without penalty. We intend to repay the DDTL using borrowings under our existing long-term credit facility, therefore, we continue to classify this term loan as long-term debt. Any remaining outstanding balances under the revolving credit facility and the DDTL are due at maturity on July 22, 2029, subject to springing maturity dates unless the Company’s liquidity equals or exceeds the principal amount of each of the respective senior notes series that remain outstanding on each of the respective springing maturity dates as follows:

(1)

October 14, 2027, if any portion of the Company’s 2021 Senior Notes Series B due January 12, 2028, in the aggregate principal amount of $15.0 million, remains outstanding on October 14, 2027, and

(2)

March 30, 2028, if any portion of the Company’s 2023 Senior Notes Series A due June 28, 2028, in the aggregate principal amount of $25.0 million, remains outstanding on March 30, 2028.

~~There~~The ~~are~~Credit noFacility ~~significant~~is ~~changes~~secured toby ~~other~~first ~~terms~~priority ~~from~~interests ~~the~~in ~~Eighth~~(1) ~~Amended~~substantially ~~and~~all ~~Restated~~of ~~Credit~~the ~~Agreement,~~tangible ~~including~~and ~~assets~~intangible ~~securing~~personal ~~the debt~~property, and equity interest ~~rates,~~of CLIH and ~~cross~~certain ~~default~~of ~~provisions~~the ~~associated~~Company’s ~~with~~U.S. ~~the~~and ~~Senior~~foreign ~~Notes~~subsidiary ~~(as~~companies ~~defined~~and ~~below~~(2) instruments evidencing intercompany indebtedness owing to the Company, ~~financial~~CLIH ~~covenants~~and orcertain of the ~~interest~~Company’s ~~coverage~~U.S. and ~~leverage~~foreign ~~ratios~~subsidiary ascompanies. ~~described~~Certain ~~below~~of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes.

~~The~~Under the Credit Facility, isthe ~~secured~~Secured byOvernight ~~first~~Financing ~~priority~~Rate ~~interests in~~ (1“SOFR”) ~~substantially~~plus ~~all~~2.00% ofto ~~the~~SOFR ~~tangible~~plus ~~and~~3.00% ~~intangible~~will ~~personal~~be ~~property,~~applied ~~and~~to ~~equity~~outstanding ~~interest~~borrowings. ofThe ~~CLIH~~available ~~and~~capacity ~~certain~~at ofany ~~the~~point ~~Company’s~~in ~~U.S.~~time ~~and~~is ~~foreign~~reduced ~~subsidiary~~by ~~companies~~outstanding borrowings and ~~(2)~~outstanding ~~instruments~~letters ~~evidencing~~of ~~intercompany~~credit ~~indebtedness~~which ~~owing~~totaled toapproximately ~~the~~$12.5 ~~Company~~million at March 31, ~~CLIH~~2026, ~~and~~resulting ~~certain~~in ofan available borrowing capacity under the ~~Company’s~~Credit UFacility of approximately $85.S5 million. ~~and~~In ~~foreign~~addition ~~subsidiary~~to ~~companies.~~indebtedness ~~Certain~~under ofthe ~~our~~Credit ~~significant~~Facility, ~~wholly~~we ~~owned~~had ~~subsidiaries~~approximately ~~are~~$6.9 ~~guarantors~~million orof ~~co-borrowers~~outstanding ~~under~~letters ~~the~~of ~~Credit~~credit ~~Facility~~and performance guarantees and ~~Senior~~bonds ~~Notes~~from other sources as of March 31, 2026.

Under the Credit Facility, the Secured Overnight Financing Rate (“SOFR”) plus 2.00% to SOFR plus 3.00% will be applied to outstanding borrowings. The available capacity at any point in time is reduced by outstanding borrowings and outstanding letters of credit which totaled approximately $11.1 million at September 30, 2025, resulting in an available borrowing capacity under the Credit Facility of approximately $131.9 million. In addition to indebtedness under the Credit Facility, we had approximately $8.0 million of outstanding letters of credit and performance guarantees and bonds from other sources as of September 30, 2025.

The Credit Facility and Senior Notes include a cross-default provision, whereby a default under one agreement may trigger a default in the other agreements.

The terms of the Credit Facility and Senior Notes require us to meet certain covenants, including, but not limited to, an interest coverage ratio (calculated as consolidated EBITDA divided by interest expense) and a leverage ratio (calculated as consolidated net indebtedness divided by consolidated EBITDA), where consolidated EBITDA (as defined in each agreement) and interest expense are calculated using the most recent four fiscal quarters. The Credit Facility has more restrictive covenants with a minimum interest coverage ratio of 3.00 to 1.00 and permits a maximum leverage ratio of 2.50 to 1.00. The Credit Facility allows non-cash charges such as impairment of assets, stock compensation and other non-cash charges to be added back in the calculation of consolidated EBITDA. The terms of our Credit Facility also allow us to negotiate in good faith to amend any ratio or requirement to preserve the original intent of the agreement if any change in accounting principles would affect the computation of any financial ratio or covenant of the Credit Facility. In accordance with the terms of the Credit Facility, our leverage ratio is 1.1020 and our interest coverage ratio is 7.8620, each for the period ended ~~September~~March 3031, ~~2025~~2026. We are in compliance with all covenants contained in our Credit Facility and Senior Notes as of ~~September~~March 3031, ~~2025~~2026.

We, along with CLIH as issuer, have senior notes outstanding that were issued through private placement transactions. Series ~~A and Series~~ B of the 2021 Senior Notes were issued in 2021 (the “2021 Senior Notes”). Series A and Series B of the 2023 Senior Notes were issued in 2023 (the “2023 Senior Notes”). The 2021 Senior Notes and the 2023 Senior Notes are collectively the “Senior ~~Notes”. We intend to repay the 2021 Senior Notes Series A at maturity in January 2026 using borrowings under the Credit Facility; therefore, we continue to classify them as long-term debt.~~

~~See Note 11 - Derivative Instruments and Hedging Activities for additional information regarding interest rate swap agreements we have entered to fix the underlying risk-free rate on our Senior Notes.~~ 12

Return to Index

~~The~~Notes”. ~~estimated~~On ~~fair~~January ~~value of total debt at September 30~~12, ~~2025 and December 31~~2026, ~~2024,~~we ~~approximated~~repaid the ~~book~~2021 ~~value~~Senior ofNotes ~~total~~Series ~~debt.~~A ~~The~~with ~~fair~~aggregate ~~value~~principal ~~was~~amount ~~estimated~~of ~~using~~$45.0 ~~Level~~million 2upon ~~inputs by calculating~~ the ~~sum~~maturity ofdate with the ~~discounted~~single ~~future~~draw ~~interest~~of ~~and~~$50.0 ~~principal~~million ~~payments~~from ~~through~~ the ~~maturity~~delayed ~~date~~draw term loan.

8.See ~~PENSION~~Note ~~AND~~10 ~~OTHER~~- ~~POSTRETIREMENT~~Derivative ~~BENEFIT~~Instruments ~~PLANS~~and Hedging Activities for additional information regarding interest rate swap agreements we have entered to fix the underlying risk-free rate on our 2023 Senior Notes.

~~Prior~~The toestimated ~~January~~fair ~~2020,~~value ~~one~~ of ~~our~~total ~~subsidiaries~~debt ~~provided~~at aMarch ~~noncontributory~~31, ~~defined~~2026 ~~benefit pension plan covering substantially all of our Dutch employees (“Dutch Plan”) who were hired prior to 2000. This pension benefit was based on years of service~~ and ~~final~~December ~~pay~~31, ~~or career average pay~~2025, ~~depending~~approximated onthe ~~when~~book ~~the~~value ~~employee~~of ~~began~~total ~~participating~~debt. The ~~Dutch~~fair ~~Plan~~value was ~~curtailed~~estimated ~~prior~~using toLevel ~~January~~2 ~~2020,~~inputs ~~and~~by ~~these~~calculating ~~employees have been moved into~~ the ~~Dutch~~sum ~~defined~~of ~~contribution plan. However,~~ the ~~unconditional~~discounted ~~indexation~~future ~~for~~interest ~~this~~and ~~group~~principal ofpayments ~~participants~~through ~~continues for so long as they remain in active service with~~ the ~~Company.~~maturity date.

~~The~~7. ~~following~~PENSION ~~table~~AND ~~summarizes~~OTHER ~~the~~POSTRETIREMENT ~~components~~BENEFIT ~~of net periodic pension cost under the Dutch Plan (in thousands):~~PLANS

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2025			2024			2025			2024
Interest cost	$	386		$	352		$	1,106		$	1,054
Expected return on plan assets		(312	)		(314	)		(893	)		(891	)
Net periodic pension cost	$	74		$	38		$	213		$	163

Prior to January 2020, one of our subsidiaries provided a noncontributory defined benefit pension plan covering substantially all of our Dutch employees who were hired prior to 2000 (“Dutch Plan”). This pension benefit was based on years of service and final pay or career average pay, depending on when the employee began participating. The Dutch Plan was curtailed prior to January 2020, and these employees have been moved into the Dutch defined contribution plan. However, the unconditional indexation for this group of participants continues for so long as they remain in active service with the Company.

9.The ~~COMMITMENTS~~components ~~AND~~of ~~CONTINGENCIES~~net periodic pension cost for the Dutch Plan include (in thousands):


	Three Months Ended
	March 31,
	2026			2025
Interest cost	$	423		$	347
Expected return on plan assets		(350	)		(280	)
Net periodic pension cost	$	73		$	67

8. COMMITMENTS AND CONTINGENCIES

We have been and may, from time to time, be named as a defendant in legal actions that arise in the ordinary course of business. These include, but are not limited to, employment-related claims and contractual disputes or claims for personal injury or property damage which occur in connection with the provision of our services and products. A liability is accrued when a loss is both probable and can be reasonably estimated.

See Note 76 - Long-term Debt, net for amounts committed under letters of credit and performance guarantees and bonds.

109. EQUITY

Treasury Stock

During the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~2026, we distributed 124,~~402~~670 ~~and 91,602~~ shares, ~~respectively,~~ of treasury stock upon vesting of stock-based awards. During the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~2026, we repurchased ~~462~~51,~~248~~781 ~~and 831,478~~ shares, ~~respectively,~~ of our common stock for $5.0 ~~million and $9~~.89 million, ~~respectively.~~of ~~The~~which ~~total~~1,695 ~~repurchased~~ shares ~~include~~valued ~~rights~~at ~~which~~$29 thousand were surrendered to us pursuant to the terms of a stock-based compensation plan in consideration of the participant’s tax burdens resulting from the issuance of common stock under ~~that~~the plan. ~~Rights surrendered to us were 4,461 and 16,915 shares valued at $47 thousand and $211 thousand for the three and nine months ended September 30, 2025, respectively.~~ Such shares of common stock, unless canceled, may be reissued for a variety of purposes such as future acquisitions, non-employee director stock awards or employee stock awards.

Dividend Policy

In March, ~~May and August 2025~~2026, we paid a quarterly cash dividend of $0.01 per share of common stock. In addition, on ~~October~~April 2229, ~~2025~~2026, we declared a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on ~~November~~May 311, ~~2025~~2026, and payable on ~~November~~June 241, ~~2025~~2026.

Return to Index

Accumulated Other Comprehensive Income (Loss)

Amounts recognized, net of income tax, in accumulated other comprehensive income (loss) consist of the following (in thousands):


	March 31, 2026			December 31, 2025
Pension and other post-retirement benefit plans - unrecognized prior service costs and net actuarial loss	$	(5,442	)	$	(5,499	)
Interest rate swaps - net gain (loss) on fair value		(312	)		(307	)
Total accumulated other comprehensive income (loss)	$	(5,754	)	$	(5,806	)

~~Return~~Retained ~~to Index~~Earnings

	September 30,2025			December 31,2024
Pension and other post-retirement benefit plans - unrecognized prior service costs and net actuarial loss	$	(5,719	)	$	(5,890	)
Interest rate swaps - net gain (loss) on fair value		(265	)		121
Total accumulated other comprehensive income (loss)	$	(5,984	)	$	(5,769	)

The beginning balances of retained earnings and total equity for the three months ended March 31, 2025 have been adjusted for certain prior period immaterial corrections. See Note 2 - Summary of Significant Accounting Policies Update.

1110. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We are exposed to market risks related to fluctuations in interest rates. To mitigate these risks, we may utilize derivative instruments in the form of interest rate swaps. We do not enter into derivative transactions for speculative purposes.

In March 2021, we entered into a forward interest rate swap agreement and carried the fair value of certain terminated variable-to-fixed swaps into the agreement in a “blend and extend” structured transaction. The purpose of this forward interest rate swap agreement iswas to fix the underlying risk-free rate, that would be associated with the anticipated issuance of new long-term debt by the Company in future periods. The forward interest rate swap would hedge the risk-free rate on forecasted long-term debt through March 2033. Risk associated with future changes in the 10-year LIBOR interest rates ~~have~~were ~~been~~ fixed up to a notional amount of $60.0 million with this instrument. The interest rate swap ~~qualifies~~qualified as a cash flow hedging instrument. ~~This~~The forward interest rate swap agreement was terminated and settled in April 2022. The hedging relationship iswas highly effective, therefore, the gain on the termination of the forward interest rate swap was included in accumulated other comprehensive income (loss). OnIn June ~~28,~~ 2023, the Company issued the 2023 Senior Notes inwith ~~the~~an aggregate principal amount of $50.0 million at fixed interest rates of 7.25% and 7.50%. The Company has elected to apply the optional expedient for hedging relationships affected by reference rate reform. Accordingly, no outstanding balance on the 2023 Senior Notes will preclude cash flow hedging with the ~~existing~~ LIBOR hedging instrument. AThe unamortized net loss ofon ~~$0.3~~this ~~million~~swap is included in accumulated other comprehensive income (loss) at ~~September~~March 3031, ~~2025.~~2026 ~~The~~of ~~unamortized~~$0.3 ~~balance~~million ~~on this swap~~ will be amortized into interest expense in accordance with the forecasted transactions or the scheduled interest payments on the 2023 Senior Notes and any future debt through March 2033.

The effect of interest rate swaps on the consolidated statements of operations is as follows (in thousands):

	Three Months Ended						~~Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2025			2024			2025			2024			Income Statement Classification
	2026			2025			Income Statement Classification
Derivatives designated as hedges:
5 year interest rate swap	$	—		$	5(12	)	$Increase (decrease) to interest expense	~~(12~~	)	$	67		~~Increase (decrease) to interest expense~~
10 year interest rate swap		(~~108~~6	)		(~~240~~208	)	Increase (decrease) to interest expense	~~(477~~	)		~~(847~~	)	~~Increase (decrease) to interest expense~~
	$	(~~108~~6	)	$	(~~235~~220	)	$	~~(489~~	)	$	~~(780~~	)

1211. FINANCIAL INSTRUMENTS

The Company’s only financial assets and liabilities which are measured at fair value on a recurring basis relate to certain aspects of the Company’s benefit plans. We use the market approach to determine the fair value of these assets and liabilities using significant other observable inputs (Level 2) with the assistance of third-party specialists. We do not have any assets or liabilities measured at fair value on a recurring basis using quoted prices in an active market (Level 1) or significant unobservable inputs (Level 3). Gains and losses related to the fair value changes in the financial assets and liabilities are recorded in general and administrative expense in the consolidated statements of operations.14

Return to Index

The following table summarizes the fair value balances (in thousands):

Fair Value Measurement at

September 30, 2025

March 31, 2026

Total

Level 1

Level 2

Level 3

Assets:

Company owned life insurance policies (1)

26,~~518~~097

—

26,~~518~~097

—

26,~~518~~097

—

26,~~518~~097

—

Liabilities:

Deferred compensation liabilities

2018,~~536~~565

—

2018,~~536~~565

—

2018,~~536~~565

—

2018,~~536~~565

—

Fair Value Measurement at

December 31, 2024

December 31, 2025

Total

Level 1

Level 2

Level 3

Assets:

Company owned life insurance policies (1)

2526,~~435~~627

—

2526,~~435~~627

—

2526,~~435~~627

—

2526,~~435~~627

—

Liabilities:

Deferred compensation liabilities

1918,~~103~~451

—

1918,~~103~~451

—

1918,~~103~~451

—

1918,~~103~~451

—

(1) Company owned life insurance policies have cash surrender value and are intended to assist in funding deferred compensation liabilities and other benefit plans.

1312. OTHER (INCOME) EXPENSE, NET

The components of other (income) expense, net, are as follows (in thousands):

	Three Months Ended						~~Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2025			2024			2025			2024
	2026			2025
(Gain) loss on sale of assets	$	(146	)	$	364		$	(369	)	$	(390	)
Gain on sale of assets	$	(1,013	)	$	(6	)
Results of non-consolidated subsidiaries		~~194~~79			(~~108~~37	)		~~401~~			~~(207~~	)
Foreign exchange (gain) loss, net		~~354~~380			~~(239~~480	)		~~841~~			~~435~~
Rents and royalties		(8—	)		(~~882~~7	)		~~(24~~	)		~~(1,683~~	)
Return on pension assets and other pension costs		(~~312~~350	)		(~~314~~280	)		~~(893~~	)		~~(891~~	)
Assets write-down, loss on lease abandonment and other exit costs		—			—			707			1,809
Assets write-down, loss on lease termination and other exit costs		639			707
Insurance recovery - business interruption and costs		(52	)		(1,151	)		(1,031	)		(3,481	)
Severance and other charges		—			2,256
Insurance recovery - property, plant and equipment		(5,253	)		(2,074	)		(6,830	)		(2,074	)
Other, net		(380	)		(778	)
Severance and other charges		—			—			2,256			824
Total other (income) expense, net	$	(645	)	$	2,335
Other, net		(367	)		(125	)		(1,280	)		(415	)
Total other (income) expense, net	$	(5,590	)	$	(4,529	)	$	(6,222	)	$	(6,073	)

During the ~~nine~~three months ended ~~September~~March 3031, ~~2025~~2026 and ~~2024~~2025, as a result of our continuous efforts in consolidating and exiting certain facilities in the U.S. and other international locations for operational efficiency, we sold property in Tulsa, Oklahoma for a net gain of $0.9 million. In addition, we recognized a write-down of the associated leasehold improvements, right of use assets and other assets and incurred lease ~~abandonment~~termination and other exit costs of $0.76 million and $10.87 million, respectively.

In February 2024, we had a fire incident at our Aberdeen, U.K. facility and we have recorded insurance recovery associated with business interruptions, increase in cost of work, and loss on property and assets during the three and nine months ended September 30, 2025 and 2024. During the three months ended September 30, 2025, Core Lab reached final settlement with the insurance company and recorded a gain of approximately $5.2 million on the insurance recovery.15

Return to Index

Foreign exchange (gain) loss, net byfor ~~currency~~the primary currencies in which we operate and those with a material effect for the period presented is summarized in the following table (in thousands):

	Three Months Ended						~~Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2025			2024			2025			2024
	2026			2025
British Pound	$	(4864	)	$	(646	)	$	~~(108~~	)	$	6
Canadian Dollar		4323			~~(13~~46	)		~~(11~~	)		60
Colombian Peso		(38	)		44			(98	)		13
Euro		(70	)		285
Euro		(30	)		201			772			266
Indonesian Rupiah		50			74
Indonesian Rupiah		100			(332	)		133			(107	)
Russian Ruble		97			(185	)
Russian Ruble		144			(4	)		(189	)		10
Other currencies, net		344			266
Swedish Krona		5			23			128			(7	)
Foreign exchange (gain) loss, net	$	380		$	480
Other currencies, net		178			(94	)		214			194
Foreign exchange (gain) loss, net	$	354		$	(239	)	$	841		$	435

1413. INCOME TAX EXPENSE (BENEFIT)

The Company recorded an income tax ~~expense~~benefit of $3(0.83) million ~~and $7.4 million~~ for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025,~~2026 ~~respectively~~ compared to income tax expense of $41.7 million ~~and $10.0 million~~ for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024, respectively~~2025. The effective tax rate for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025,~~2026 ~~was 20.5%~~ and ~~22.7%~~2025, ~~respectively. The effective tax rate for the three and nine months ended September 30, 2024,~~ was 2825.10% and 2896.82%, respectively . The effective tax rate for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~2026, was primarily impacted by the earnings mix of jurisdictions subject to tax for the period and ~~changes~~items ~~in uncertain tax position in certain jurisdictions which is~~ discrete to the quarter. The effective tax rate for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024~~2025, was impacted by ~~the~~approximately ~~earnings~~$1.4 ~~mix~~million of ~~jurisdictions~~additional ~~subject~~tax toexpense ~~tax~~recorded for items discrete to the ~~period~~quarter. ~~and~~These discrete items ~~discrete~~are toprimarily associated with the ~~quarter~~finalization of certain tax jurisdictions’ return to provision assessments due to changes in estimates.

On14. ~~July~~EARNINGS ~~4, 2025, the “One Big Beautiful Bill Act”~~ (~~the “Act”~~LOSS) ~~was~~PER enacted into law. The Act includes significant provisions, including tax cut extensions and modifications to the U.S. and international tax frameworks. We are evaluating the impact of these legislative changes as additional guidance becomes available. Currently, we do not believe legislation will have a material impact on our tax expense. SHARE

15We compute basic earnings (loss) per share by dividing net income (loss) attributable to Core Laboratories Inc. ~~EARNINGS~~by ~~PER~~the ~~SHARE~~number of weighted average common shares outstanding during the period. Diluted earnings (loss) per share includes the incremental effect of contingently issuable shares from performance and restricted stock awards, as determined using the treasury stock method.

WeThe ~~compute~~following ~~basic~~table ~~earnings~~summarizes ~~per share by dividing net income attributable to Core Laboratories Inc. by~~ the ~~number~~calculation of weighted average common shares outstanding ~~during~~used ~~the~~in ~~period. Diluted earnings per share includes~~ the ~~incremental~~computation ~~effect~~ of ~~contingently~~basic ~~issuable shares from performance~~ and ~~restricted~~diluted ~~stock~~earnings ~~awards,~~(loss) asper ~~determined~~share ~~using~~(in ~~the treasury stock method.~~ thousands):

The following table summarizes the calculation of weighted average common shares outstanding used in the computation of basic and diluted earnings per share (in thousands):


	Three Months Ended
	March 31,
	2026		2025
Weighted average common shares outstanding - basic		46,073		46,773
Effect of dilutive securities:
Restricted shares		—		—
Performance shares		—		—
Weighted average common shares outstanding - assuming dilution		46,073		46,773

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
Weighted average common shares outstanding - basic		46,263		46,922		46,552		46,897
Effect of dilutive securities:
Restricted shares		31		108		39		76
Performance shares		784		790		790		717
Weighted average common shares outstanding - diluted		47,078		47,820		47,381		47,690

For the three months ended March 31, 2026 and 2025, the number of Core Laboratories Inc. restricted and performance shares of common stock that were excluded from the diluted earnings (loss) per share calculation as their impact would be antidilutive, were as follows (in thousands):


	Three Months Ended
	March 31,
	2026		2025
Restricted shares		89		77
Performance shares		887		730

Return to Index

1615. SEGMENT REPORTING

We operate our business in two segments. These complementary operating segments provide different services and products and utilize different technologies for evaluating and improving reservoir performance and increasing oil and gas recovery from new and existing fields.

•

Reservoir Description: Encompasses the characterization of petroleum reservoir rock and reservoir fluids samples to increase production and improve recovery of crude oil and natural gas from our clients’ reservoirs. We provide laboratory-based analytical and field services to characterize properties of crude oil and crude oil-derived products to the oil and gas industry. Services associated with these fluids include determining the quality and measuring the quantity of the reservoir fluids and their derived products, such as gasoline, diesel and biofuels. We also provide proprietary and joint industry studies based on these types of analyses and manufacture associated laboratory equipment. In addition, we provide reservoir description capabilities that support various activities associated with energy transition projects, including services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities around lithium and other elements necessary for energy storage.

•

Production Enhancement: Includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. We provide integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.

We use the same accounting policies to prepare our operating segment results as are used to prepare our consolidated financial statements. All interest and other non-operating income (expense) is attributable to Corporate & Other and is not allocated to specific operating segments.

Our chief operating decision maker (“CODM”) is our Chief Executive Officer, who also serves as Chairman of the Board of Directors. The CODM uses revenue from unaffiliated clients and segment operating income to allocate resources, primarily for working capital, staffing and capital expenditures, during the annual budgeting process and monthly when comparing actual results to budgeted and forecasted results.

Summarized financial information of our operating segments is shown in the following table (in thousands):

1917

Return to Index

	ReservoirDescription			ProductionEnhancement			Corporate &Other (1)			Consolidated
Three months ended September 30, 2025
Three months ended March 31, 2026
CODM Measure - Revenue from unaffiliated clients	$	8881,~~224~~931		$	4639,~~297~~866		$	—		$	~~134~~121,~~521~~797
Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income:
Inter-segment revenue		79118			4129			(~~120~~147	)		—
Cost of services and product sales		6768,~~156~~107			3733,~~553~~629			~~192~~337			~~104~~102,~~901~~073
General and administrative expense (2)		69,~~900~~970			34,~~788~~748			—			1014,~~688~~718
Depreciation and amortization		2,~~594~~779			~~1,000~~985			—			3,~~594~~764
Other operating (income) expense, net (3)		(~~5,232~~431	)		(~~306~~131	)		(~~406~~463	)		(51,~~944~~025	)
Foreign exchange (gain) loss, net (3)		~~311~~478			(76140	)		~~119~~42			~~354~~380
CODM Measure - Segment operating income		161,~~574~~146			~~4,379~~804			(2563	)		201,~~928~~887
Supplemental Disclosures:
Total assets		~~322~~333,~~047~~341			~~143~~141,~~219~~142			~~126~~113,~~094~~245			~~591~~587,~~360~~728
Capital expenditures		24,~~706~~509			~~183~~306			~~142~~76			34,~~031~~891
Three months ended September 30, 2024
Three months ended March 31, 2025
CODM Measure - Revenue from unaffiliated clients	$	8880,~~840~~897		$	4542,~~557~~688		$	—		$	~~134~~123,~~397~~585
Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income:
Inter-segment revenue		3416			~~125~~68			(~~159~~84	)		—
Cost of services and product sales		6864,~~544~~605			3834,~~490~~761			~~(229~~103	)		~~106~~99,~~805~~469
General and administrative expense (2)		59,~~542~~038			34,~~100~~609			—			813,~~642~~647
Depreciation and amortization		2,~~618~~615			1,~~058~~102			—			3,~~676~~717
Other operating (income) expense, net (3)		(42,~~160~~128	)		~~(81~~539	)		(49812	)		(41,~~290~~855	)
Foreign exchange (gain) loss, net (3)		~~(157~~188	)		~~(117~~242	)		3550			~~(239~~480	)
CODM Measure - Segment operating income		162,~~487~~339			31,~~232~~503			84575			194,~~803~~417
Supplemental Disclosures:
Total assets		322,001			154,995			123,470			600,466
Total assets (4)		318,436			149,297			118,510			586,243
Capital expenditures		2,~~273~~422			~~427~~1,129			2928			23,~~729~~579
Nine months ended September 30, 2025
CODM Measure - Revenue from unaffiliated clients	$	255,401		$	132,864		$	—		$	388,265
Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income:
Inter-segment revenue		136			155			(291	)		—
Cost of services and product sales		198,701			108,690			680			308,071
General and administrative expense (2)		22,754			12,045			—			34,799
Depreciation and amortization		7,854			3,127			—			10,981
Other operating (income) expense, net (3)		(5,576	)		143			(1,630	)		(7,063	)
Foreign exchange (gain) loss, net (3)		688			(16	)		169			841
CODM Measure - Segment operating income		31,116			9,030			490			40,636
Supplemental Disclosures:
Total assets		322,047			143,219			126,094			591,360
Capital expenditures		8,880			1,887			170			10,937
Nine months ended September 30, 2024
CODM Measure - Revenue from unaffiliated clients	$	259,353		$	135,258		$	—		$	394,611
Reconciliation of CODM measure - revenue from unaffiliated clients to segment operating income:
Inter-segment revenue		71			187			(258	)		—
Cost of services and product sales		201,989			112,207			127			314,323
General and administrative expense (2)		19,842			10,848			—			30,690
Depreciation and amortization		8,089			3,200			—			11,289
Other operating (income) expense, net (3)		(5,753	)		(55	)		(700	)		(6,508	)
Foreign exchange (gain) loss, net (3)		434			36			(35	)		435
CODM Measure - Segment operating income		34,823			9,209			350			44,382
Supplemental Disclosures:
Total assets		322,001			154,995			123,470			600,466
Capital expenditures		7,481			914			252			8,647

(1) "Corporate & Other" represents those items that are not directly related to a particular operating segment and eliminations.

(2) General and administrative expense is presented as a total amount to the CODM and consists primarily of employee compensation costs, professional fees and information technology costs.

(3) Other ~~remaining~~operating ~~balance~~(income) isexpense, net and foreign currency exchange (loss), net are included in the consolidated statement of operations as other (income) expense, net. See Note 1312 - Other (income) expense, net for further details.

20(4) Total assets at March 31, 2025 included in the Reservoir Description operating segment have been adjusted for certain prior period immaterial corrections. See Note 2 - Significant Accounting Policies Update.

Return to Index

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion highlights the current operating environment and summarizes the financial position of Core Laboratories Inc. and its subsidiaries as of ~~September~~March 3031, ~~2025~~2026, and should be read in conjunction with (i) the unaudited interim consolidated financial statements and notes thereto included elsewhere in this Quarterly Report and (ii) the audited consolidated financial statements and accompanying notes thereto included in our ~~2024~~2025 Annual Report on Form 10-K for the year ended December 31, ~~2024~~2025.

General

Core Laboratories Inc. is a Delaware corporation. It was established in 1936 and is one of the world's leading providers of proprietary and patented reservoir description and production enhancement services and products to the oil and gas industry. These services and products can enable our clients to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. We make measurements on reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. In addition, we assist clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Core Laboratories Inc. has over 70 offices in more than 50 countries and employs approximately 3,300 people worldwide.

References to “Core Lab”, “Core Laboratories”, the “Company”, “we”, “our” and similar phrases are used throughout this Quarterly Report and relate collectively to Core Laboratories Inc. and its consolidated affiliates.

•

Reservoir Description: Encompasses the characterization of petroleum reservoir rock and reservoir fluids samples to increase production and improve recovery of crude oil and natural gas from our clients'’ reservoirs. We provide laboratory-based analytical and field services to characterize properties of crude oil and crude oil-derived products to the oil and gas industry. Services associated with these fluids include determining the quality and measuring the quantity of the reservoir fluids and their derived products, such as gasoline, diesel and biofuels. We also provide proprietary and joint industry studies based on these types of analyses and manufacture associated laboratory equipment. In addition, we provide reservoir description capabilities that support various activities associated with energy transition projects, including services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities around lithium and other elements necessary for energy storage.

•

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (“Exchange Act”). Certain statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations section, including those under the headings “Outlook” and “Liquidity and Capital Resources”, and in other parts of this Quarterly Report, are forward-looking. In addition, from time to time, we may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. Forward-looking statements can be identified by the use of forward-looking terminology such as “may”, “will”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, or other similar words, including statements as to the intent, belief, or current expectations of our directors, officers, and management with respect to our future operations, performance, or positions or

2119

Return to Index

which contain other forward-looking information. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. While management believes that these forward-looking statements are reasonable as and when made, no assurances can be given that the future results indicated, whether expressed or implied, will be achieved. While we believe that these statements are and will be accurate, our actual results and experience may differ materially from the anticipated results or other expectations expressed in our statements due to a variety of risks and uncertainties.

We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of some of the foregoing risks and uncertainties, see Part II, “Item 1A - Risk Factors” of this Quarterly Report and “Item 1A - Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, ~~2024~~2025, filed by us with the Securities and Exchange Commission (“SEC”).

Outlook

~~According~~Currently, toglobal ~~the~~oil ~~latest~~inventories ~~reports~~are ~~from~~low ~~the~~relative ~~U.S.~~to ~~Energy~~historical ~~Information Administration~~levels, ~~the~~and ~~International~~with ~~Energy~~continued ~~Agency~~supply ~~(“IEA”)~~restrictions ~~and~~from the Organization of the Petroleum Exporting Countries and other oil producing nations (“OPEC+”), global ~~demand~~supply ~~for crude oil and natural gas~~ is expected to ~~continue~~be ~~increasing~~managed ~~in 2025~~ and ~~beyond.~~maintained ~~New~~at ~~tariffs~~a ~~announced~~level byto ~~the~~meet ~~U.S.~~or ~~during~~exceed ~~the~~forecasted ~~year~~growth ~~have~~in ~~triggered~~oil ~~global~~demand ~~trade~~for ~~negotiations and have raised~~ the ~~level~~next offew ~~uncertainty~~years. ~~for~~During ~~global~~2023 ~~economies.~~and ~~Additionally~~2024, OPEC+ ~~affirmed~~and ~~their~~its ~~decision~~key tomember, ~~proceed~~Saudi ~~with~~Arabia, aannounced ~~gradual~~several ~~return~~mandatory ofand ~~2.2~~voluntary ~~million~~reductions ~~barrels~~in ~~of daily~~ production. byThe ~~removing~~uncertainty around the ~~voluntary~~impact ~~production~~global ~~restrictions~~trade ~~established~~negotiations inmay ~~2023.~~have ~~The~~on ~~gradual~~global ~~increase~~economies incombined ~~production~~with ~~from~~ OPEC+’s ~~began~~announcement inof ~~May~~increased ~~2025 with incremental increases in~~ production ~~expected~~quotas ~~through~~has ~~September~~also ~~2026,~~increased ~~which~~the ~~could~~likelihood ~~create~~of a surplus in supply ~~and~~causing ~~lead~~global toinventory ~~lower~~levels ~~commodity~~of ~~prices.~~crude ~~OPEC~~oil ~~also~~to ~~published~~rise. anIn ~~updated~~May ~~“compensation~~2025, ~~plan”~~OPEC+ ~~which~~began ~~shows~~to ~~committed~~gradually ~~reductions~~increase in production ~~for~~and ~~countries~~unwind ~~that~~voluntary ~~produced~~production ~~volumes~~cuts ~~over~~through ~~their~~September ~~committed quotas since January 2024~~2026, which ifin ~~complied~~turn ~~with,~~could ~~should~~create ~~partially~~a ~~offset~~surplus ~~the~~in ~~scheduled~~supply ~~increases~~and tolead ~~production quotas. In each announcement from OPEC+ regarding the production increases, they have also stated they will continue~~ to ~~hold~~even ~~monthly~~lower ~~meetings~~commodity ~~to review market conditions, conformity, and compensation~~prices.

~~The~~Recent ~~uncertainty~~geopolitical ~~around~~developments, including the ~~impact~~escalation ~~global~~of ~~trade~~armed ~~negotiations~~conflict ~~may~~in ~~have~~the onMiddle ~~global~~East, ~~economies~~have ~~combined~~dramatically ~~with~~shifted ~~OPEC+’s~~the ~~announcement~~crude ofoil ~~increased~~supply-demand ~~production~~balance. ~~quotas~~On ~~has~~February ~~also~~28, ~~increased~~2026 the ~~likelihood~~United ~~that~~States ~~global~~and ~~inventory~~Israel ~~levels~~initiated ofair ~~crude~~strikes ~~oil~~against ~~will~~Iranian ~~rise,~~military ~~thereby~~targets ~~contributing~~and ~~to weaker crude oil prices~~leadership. ~~The~~Since ~~Company believes that activity levels associated with smaller-scale~~then, ~~short-cycle~~retaliation ~~crude~~by ~~oil~~Iran ~~development~~against ~~projects~~United ~~will~~States beand ~~more~~Israeli ~~sensitive~~interests toin athe ~~decrease~~Middle ~~and/or~~East ~~continued~~has ~~volatility~~been ~~of crude-oil prices~~widespread. As ~~such,~~of wethe ~~expect~~date ~~changes~~of inthe ~~crude~~filing ~~oil~~of ~~prices~~this ~~will~~Quarterly ~~have~~Report, amilitary ~~greater~~activity ~~impact on drilling~~ and ~~completion~~hostilities ~~activity~~continue ~~levels~~to escalate in the ~~U.S.~~Middle ~~onshore~~East, ~~market.~~and ~~Outside~~ the ~~U.S.,~~situation ~~large-scale~~throughout ~~international~~the ~~oil~~region ~~and~~remains ~~gas~~volatile, ~~projects~~with ~~are~~the ~~expected~~potential tofor becontinued ~~more~~escalation ~~resilient~~into toa ~~the~~broader ~~near-term~~and ~~volatility~~more ofsustained ~~crude-oil~~regional ~~prices,~~conflict. ~~and~~While the Company ~~anticipates~~believes ~~current~~the ~~client~~fundamentals ~~projects~~for toenergy-related ~~continue~~services asremain ~~planned~~stable, ~~and~~near-term ~~additional~~volatility ~~projects~~in ~~scheduled~~commodity ~~this~~prices ~~year~~meaningfully toraises ~~also~~the belevel ~~executed~~of ~~as planned~~uncertainty. ~~Recently,~~The ~~revised~~Company ~~IEA~~is ~~field~~monitoring ~~data~~developments ~~showed~~with ~~that~~respect ato ~~steeper~~the ~~natural~~ongoing ~~decline~~military ~~rate~~conflict ~~may~~with ~~represent a dominant long-term supply risk~~Iran, ~~where~~including the ~~agency~~impact ~~projected~~on aglobal ~~sustained~~commodity ~~upstream~~prices ~~investment~~and ofpotential ~~approximately~~shipping ~~$540~~and tologistics ~~$570~~disruptions, ~~billion~~which ~~per~~could ~~year~~affect isour ~~required~~customers toand ~~prevent~~their ~~disruptive~~activity ~~declines~~levels ~~and~~in tothe ~~avoid price volatility~~region.

The ~~ongoing~~Company ~~geopolitical~~believes ~~conflicts~~that ~~between~~activity ~~Russia~~levels ~~and~~associated ~~Ukraine~~with ~~and~~smaller-scale, inshort-cycle ~~the~~crude ~~Middle~~oil ~~East,~~development ~~along~~projects ~~with~~will ~~associated~~be more sensitive to a decrease and/or ~~expanded~~continued ~~sanctions~~volatility inof ~~the~~crude-oil ~~United~~prices. ~~States~~As such, ~~the~~we ~~European~~expect ~~Union,~~changes ~~the~~in ~~United~~crude ~~Kingdom~~oil ~~and~~prices ~~other~~will ~~countries~~have ~~continue~~a togreater ~~cause~~impact ~~disruptions~~on todrilling ~~traditional~~and ~~maritime~~completion ~~supply~~activity ~~chains~~levels ~~and~~in the ~~trading~~U.S. ofonshore ~~crude~~market ~~oil~~which ~~and~~could ~~derived~~directly ~~products,~~affect ~~such~~demand asfor ~~diesel~~our ~~fuel.~~well ~~These~~completion ~~disruptions~~services toand products. Outside the ~~trading~~U.S., ~~and~~large-scale ~~maritime~~international ~~transportation~~oil ofand ~~crude~~gas ~~oil,~~projects ~~also~~are ~~impact~~expected ~~the~~to ~~demand~~be ~~for~~more ~~the~~resilient ~~Company's~~to ~~associated~~the ~~laboratory~~near-term ~~assay~~volatility ~~services.~~of ~~Although~~crude-oil ~~demand~~prices, ~~for~~and the Company’s ~~laboratory~~anticipates ~~assay~~client ~~analysis~~projects ~~services~~will ~~continued~~continue to ~~increase~~be ~~during~~executed ~~the~~as ~~first~~planned. ~~nine~~Recently, ~~months~~revised ofIEA ~~2025,~~field ~~these~~data ~~geopolitical~~showed ~~conflicts~~that ~~and~~a ~~associated~~steeper ~~sanctions~~natural ~~continue~~decline torate ~~create~~may represent a ~~higher~~dominant ~~level~~long-term ofsupply ~~uncertainty.~~risk, Wewhere ~~have~~the noagency ~~way~~projected toa ~~predict~~sustained ~~the~~upstream ~~progress~~investment orof ~~outcome~~approximately of$540 ~~these~~to ~~events,~~$570 ~~and~~billion ~~any~~per ~~resulting~~year ~~government~~is ~~responses~~required ~~are~~to ~~fluid~~prevent disruptive declines and ~~beyond~~to ~~our~~avoid ~~control~~supply shortages and price volatility.

WeThe ~~continue~~ongoing togeopolitical ~~focus~~conflicts onbetween ~~large-scale~~Russia ~~core~~and ~~analyses~~Ukraine and ~~reservoir~~between ~~fluids~~the ~~characterization~~United ~~studies~~States, inIsrael ~~most~~and ~~oil-producing~~Iran, ~~regions~~along ~~across~~with associated and expanded sanctions in the ~~globe~~United States, ~~which~~the ~~include~~European ~~both~~Union, ~~newly~~the ~~developed~~United ~~fields~~Kingdom and ~~brownfield~~other ~~extensions~~countries incontinue ~~many~~to ~~offshore~~cause ~~developments~~disruptions into ~~both~~traditional maritime supply chains and the Utrading of crude oil and derived products, such as diesel fuel.S. The effective closure of the Strait of Hormuz with the onset of military conflict in Iran has further exacerbated maritime trade flows of crude oil and ~~internationally~~derived products. InApproximately 20% of global crude oil production passes through the UStrait of Hormuz and a substantial portion of that crude oil remains stranded.~~S.,~~ weThese ~~are~~disruptions ~~involved~~to inthe ~~projects~~trading ~~with~~and ~~many~~maritime transport of crude oil directly impact demand for the ~~onshore~~Company’s ~~unconventional~~associated ~~basins~~laboratory assay services. Although demand for the Company’s laboratory assay services continued to increase during 2025, asgeopolitical ~~well~~conflict asand associated sanctions continue to create a

2220

Return to Index

~~offshore~~higher ~~projects~~level ~~in the Gulf~~ of ~~Mexico~~uncertainty. ~~Outside~~We ~~the~~have ~~U.S.,~~no weway ~~continue~~ to ~~work~~predict ~~on many small and large-scale projects analyzing reservoir rock and fluid samples in every major producing region of~~ the ~~world.~~progress ~~Notable~~or ~~larger~~outcome ~~projects are in locations such as offshore South America, Australia, West Africa and the Middle East. Analysis and measurement services also occur in every major producing region~~ of ~~the~~these ~~world. Additionally~~events, ~~some of our major clients have increased their investment in projects to capture~~ and ~~sequester~~any ~~carbon~~resulting ~~dioxide~~government inresponses ~~recent~~are ~~years~~fluid ~~that has expanded the Company’s activities on these projects beginning in 2024~~ and ~~into~~beyond ~~2025~~our control.

~~Our~~We ~~major clients~~ continue to focus on ~~capital~~large-scale ~~management,~~core ~~return~~analyses onand ~~invested~~reservoir ~~capital,~~fluids ~~free~~characterization ~~cash~~studies ~~flow~~in ~~and~~most ~~returning~~oil-producing ~~capital~~regions toacross ~~their~~the ~~shareholders~~globe, aswhich ~~opposed~~include toboth anewly ~~focus~~developed onfields ~~production~~and ~~growth.~~brownfield ~~The~~extensions ~~companies~~in ~~adopting~~many ~~value~~offshore ~~versus~~developments ~~volume~~in ~~metrics~~both ~~tend~~the toU.S. beand internationally. In the ~~more~~U.S. ~~technologically~~we ~~sophisticated~~are ~~operators~~involved in projects in many of the onshore unconventional basins and ~~form~~offshore projects in the ~~foundation~~Gulf of ~~Core~~Mexico. ~~Lab’s~~Outside ~~worldwide~~the ~~client base~~U.S. Aswe ~~oil~~continue to work on many smaller and ~~gas~~large-scale ~~commodity~~projects ~~prices~~analyzing ~~stabilize~~crude oil and derived products in ~~the~~every ~~mid-to-long-term,~~major producing region of the ~~Company~~world. ~~expects~~Notable ~~our~~larger ~~clients’~~projects ~~activities~~are ~~associated~~in ~~with~~locations ~~increasing~~such ~~oil~~as Guyana and ~~gas~~Suriname ~~reserves~~located offshore South America, Australia, West Africa and ~~production~~the ~~levels~~Middle ~~will~~East. ~~continue~~Analysis toand ~~increase~~measurement of crude oil derived products also occur in every major producing region of the ~~coming~~world. ~~years~~Additionally, some of our major clients have increased their investment in projects to capture and sequester carbon dioxide.

23Our major clients continue to focus on capital management, return on invested capital, free cash flow, and returning capital to their shareholders, as opposed to a focus on production growth. The companies adopting value versus volume metrics tend to be the more technologically sophisticated operators and form the foundation of Core Lab’s worldwide client base. The Company expects our clients’ activities associated with increasing oil and gas reserves and production levels will continue to increase in the coming years.

Return to Index

Results of Operations

Our results of operations as a percentage of applicable revenue are as follows (in thousands):

	Three Months Ended September 30,
	Three Months Ended March 31,
	2025				2024				$ Change			% Change
	2026				2025				$ Change			% Change
REVENUE:
Services	$	~~101~~94,~~125~~252		7577%	$	9895,~~842~~091		7477%	$	~~2,283~~(839	)	2(1)%
Product sales		3327,~~396~~545		2523%		3528,~~555~~494		2623%		(~~2,159~~949	)	(63)%
Total revenue		~~134~~121,~~521~~797		100%		~~134~~123,~~397~~585		100%		~~124~~(1,788	)	0(1)%
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below*		7476,~~896~~115		7481%		7572,~~503~~980		7677%		~~(607~~3,135	)	~~(1)~~4%
Cost of product sales, exclusive of depreciation expense shown below*		3025,~~005~~958		9094%		3126,~~302~~489		8893%		(~~1,297~~531	)	(42)%
Total cost of services and product sales		~~104~~102,~~901~~073		7884%		~~106~~99,~~805~~469		7980%		(12,~~904~~604	)	~~(2)~~3%
General and administrative expense, exclusive of depreciation expense shown below		1014,~~688~~718		812%		813,~~642~~647		611%		21,~~046~~071		248%
Depreciation and amortization		3,~~594~~764		3%		3,~~676~~717		3%		~~(82~~47	)	~~(2)~~1%
Other (income) expense, net		(~~5,590~~645	)	(41)%		(42,~~529~~335	)	~~(3)~~2%		(12,~~061~~980	)	~~23%~~NM
OPERATING INCOME		201,~~928~~887		162%		194,~~803~~417		154%		1(2,~~125~~530	)	6(57)%
Interest expense		2,~~650~~891		2%		32,~~108~~602		2%		~~(458~~289	)	~~(15)~~11%
Income before income taxes		18,278		14%		16,695		12%		1,583		9%
Income (loss) before income taxes		(1,004	)	(1)%		1,815		1%		(2,819	)	NM
Income tax expense		3,754		3%		4,691		3%		(937	)	(20)%
Income tax expense (benefit)		(251	)	—%		1,746		1%		(1,997	)	NM
Net income		14,524		11%		12,004		9%		2,520		21%
Net income (loss)		(753	)	(1)%		69		—%		(822	)	NM
Net income attributable to non-controlling interest		~~285~~36		—%		~~259~~223		—%		26(187	)	NM
Net income attributable to Core Laboratories Inc.	$	14,239		11%	$	11,745		9%	$	2,494		21%
Net income (loss) attributable to Core Laboratories Inc.	$	(789	)	(1)%	$	(154	)	—%	$	(635	)	412%
Other Data:
Current ratio (1)	2.3705:1				2.4821:1
Debt to EBITDA ratio (2)	1.1834:1				1.5837:1
Debt to Adjusted EBITDA ratio (3)	1.1020:1				1.4731:1

“NM” means not meaningful

*Percentage based on applicable revenue rather than total revenue

(1)

Current ratio is calculated as follows: current assets divided by current liabilities.

(2)

Debt to EBITDA ratio is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation, amortization and certain non-cash adjustments.

(3)

Debt to Adjusted EBITDA ratio (as defined in our Credit Facility) is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation, amortization, impairments, severance and certain non-cash adjustments.

2422

Return to Index

	Three Months Ended
	September 30, 2025				June 30, 2025				$ Change			% Change
	March 31, 2026				December 31, 2025				$ Change			% Change
REVENUE:
Services	$	~~101~~94,~~125~~252		7577%	$	96106,~~219~~987		7477%	$	4(12,~~906~~735	)	5(12)%
Product sales		3327,~~396~~545		2523%		3331,~~940~~268		2623%		(~~544~~3,723	)	(212)%
Total revenue		~~134~~121,~~521~~797		100%		~~130~~138,~~159~~255		100%		4(16,~~362~~458	)	3(12)%
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below*		7476,~~896~~115		7481%		7480,~~053~~277		7775%		~~843~~(4,162	)	1(5)%
Cost of product sales, exclusive of depreciation expense shown below*		3025,~~005~~958		9094%		29,~~648~~239		8794%		~~357~~(3,281	)	1(11)%
Total cost of services and product sales		~~104~~102,~~901~~073		7884%		~~103~~109,~~701~~516		8079%		1(7,~~200~~443	)	1(7)%
General and administrative expense, exclusive of depreciation expense shown below		1014,~~688~~718		812%		10,~~464~~631		8%		~~224~~4,087		238%
Depreciation and amortization		3,~~594~~764		3%		3,~~670~~668		3%		~~(76~~96	)	~~(2)~~3%
Other (income) expense, net		(~~5,590~~645	)	(41)%		(21,~~967~~392	)	(21)%		~~(2,623~~747	)	88(54)%
OPERATING INCOME		201,~~928~~887		162%		15,~~291~~832		1211%		5(13,~~637~~945	)	37(88)%
Interest expense		2,~~650~~891		2%		2,~~711~~609		2%		~~(61~~282	)	~~(2)~~11%
Income before income taxes		18,278		14%		12,580		10%		5,698		45%
Income (loss) before income taxes		(1,004	)	(1)%		13,223		10%		(14,227	)	NM
Income tax expense		3,754		3%		1,911		1%		1,843		96%
Income tax expense (benefit)		(251	)	—%		8,094		6%		(8,345	)	NM
Net income		14,524		11%		10,669		8%		3,855		36%
Net income (loss)		(753	)	(1)%		5,129		4%		(5,882	)	NM
Net income attributable to non-controlling interest		~~285~~36		—%		33181		—%		~~252~~(145	)	NM
Net income attributable to Core Laboratories Inc.	$	14,239		11%	$	10,636		8%	$	3,603		34%
Net income (loss) attributable to Core Laboratories Inc.	$	(789	)	(1)%	$	4,948		4%	$	(5,737	)	NM
Other Data:
Current ratio (1)	2.3705:1				2.2702:1
Debt to EBITDA ratio (2)	1.1834:1				1.3320:1
Debt to Adjusted EBITDA ratio (3)	1.1020:1				1.2710:1

“NM” means not meaningful

*Percentage based on applicable revenue rather than total revenue

(1)

Current ratio is calculated as follows: current assets divided by current liabilities.

(2)

Debt to EBITDA ratio is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation and amortization and certain non-cash adjustments.

(3)

2523

Return to Index

	Nine Months Ended September 30,
	2025				2024				$ Change			% Change
REVENUE:
Services	$	292,435		75%	$	291,674		74%	$	761		0%
Product sales		95,830		25%		102,937		26%		(7,107	)	(7)%
Total revenue		388,265		100%		394,611		100%		(6,346	)	(2)%
OPERATING EXPENSES:
Cost of services, exclusive of depreciation expense shown below*		221,929		76%		224,191		77%		(2,262	)	(1)%
Cost of product sales, exclusive of depreciation expense shown below*		86,142		90%		90,132		88%		(3,990	)	(4)%
Total cost of services and product sales		308,071		79%		314,323		80%		(6,252	)	(2)%
General and administrative expense, exclusive of depreciation expense shown below		34,799		9%		30,690		8%		4,109		13%
Depreciation and amortization		10,981		3%		11,289		3%		(308	)	(3)%
Other (income) expense, net		(6,222	)	(2)%		(6,073	)	(2)%		(149	)	2%
OPERATING INCOME		40,636		10%		44,382		11%		(3,746	)	(8)%
Interest expense		7,963		2%		9,740		2%		(1,777	)	(18)%
Income before income taxes		32,673		8%		34,642		9%		(1,969	)	(6)%
Income tax expense		7,411		2%		9,958		3%		(2,547	)	(26)%
Net income		25,262		7%		24,684		6%		578		2%
Net income attributable to non-controlling interest		541		—%		687		—%		(146	)	NM
Net income attributable to Core Laboratories Inc.	$	24,721		6%	$	23,997		6%	$	724		3%
Other Data:
Current ratio (1)	2.37:1				2.48:1
Debt to EBITDA ratio (2)	1.18:1				1.58:1
Debt to Adjusted EBITDA ratio (3)	1.10:1				1.47:1

Operating Results for the Three Months Ended March 31, 2026 compared to the Three Months Ended March 31, 2025 and December 31, 2025

“NM” means not meaningful

*Percentage based on applicable revenue rather than total revenue

Current ratio is calculated as follows: current assets divided by current liabilities.

Debt to EBITDA ratio is calculated as follows: debt less cash divided by the sum of consolidated net income plus interest, taxes, depreciation and amortization and certain non-cash adjustments.

Operating Results for the Three Months Ended September 30, 2025 compared to the Three Months Ended September 30, 2024 and June 30, 2025 and for the Nine Months Ended September 30, 2025 compared to the Nine Months Ended September 30, 2024

Service Revenue

Service revenue is primarily tied to activities associated with the exploration, appraisal, development and production of oil, gas and derived products outside the U.S. For the three months ended ~~September~~March 3031, ~~2025~~2026, service revenue was $~~101~~94.13 million, ana ~~increase~~decrease of 21% year-over-year and ana ~~increase~~decrease of 512% sequentially. Year-over-year, revenues ~~increased~~decreased primarily due to ~~the~~lower ~~increase~~activity levels in the international markets partially offset by ~~lower~~increased activity ~~level~~ in the U.S. market. ~~Despite~~Revenue ~~disruptions~~was ~~from~~negatively impacted by the ongoing geopolitical conflicts in the Middle East, Russia and Ukraine, and expanded sanctions ~~throughout~~previously ~~the~~discussed, ~~first~~which ~~nine~~disrupted ~~months~~our ofclient ~~2025~~activity, wefield ~~continue~~access toand ~~see~~laboratory ~~recovery~~operations inacross ~~demand~~certain ~~for~~international ~~our~~markets. ~~laboratory~~The ~~crude~~supply-~~assay~~chain ~~services~~disruptions, ~~during~~delays ~~the~~and ~~third~~rerouting ~~quarter~~ of ~~2025~~crude oil and ~~continued~~derived ~~growth~~products inthrough ~~well~~the ~~completion~~Strait ~~diagnostic~~of Hormuz negatively impacted our laboratory assay services inand ~~certain~~regional ~~international~~studies. ~~markets~~Additionally, ~~when~~severe ~~compared~~weather toacross North America, Europe and the ~~same~~Mediterranean ~~period~~region, innegatively ~~2024.~~impacted ~~Service~~certain ~~revenue~~operations inand ~~2025~~delayed ~~has~~our client activity.

26Sequentially, the decrease in service revenue was primarily due to lower demand for laboratory assay services in several international regions. As discussed above, revenue has been impacted by the ongoing geopolitical conflicts, particularly the Middle East, expanded sanctions that have caused disruptions to certain energy infrastructure, such as restricted field access, temporary declines in the trading and maritime transportation of crude oil and derived products, as well as the weather events across several regions discussed above.

Return to Index

been negatively impacted by certain projects that were planned and scheduled but were canceled, as the wells drilled by our clients were determined to be uneconomical or unsuccessful.

Sequentially, the increase in service revenue was primarily due to an increase in demand for laboratory crude-assay services in international markets while the U.S. market remained relatively flat. As discussed above, the expanded sanctions imposed throughout the year have caused a temporary disruption in the trading and maritime transportation of crude oil and derived products that slowed the growth of laboratory crude-assay revenue during 2025.

For the nine months ended September 30, 2025, service revenue was $292.4 million, relatively flat compared to the same period in the prior year. Year-over-year, the demand for laboratory crude-assay services and well completion diagnostic services continued to grow in the international markets. Additionally, reservoir rock and fluid analysis services have been negatively impacted due to the decline in international offshore commercial success rates for exploration and appraisal well projects, as discussed above.

Product Sales Revenue

Product sales are primarily tied to U.S. onshore drilling and completion activities and product sales to international markets. Product sales to international markets are typically sold and shipped in bulk, and revenue can vary from one quarter to another. For the three months ended ~~September~~March 3031, ~~2025~~2026, product sales revenue of $3327.45 million decreased 63% year-over-year and 212% sequentially. ~~The~~Year-over-year, the decrease was ~~driven~~primarily bydue to the lower level of U.S. onshore drilling and completion activity ~~onshore~~and inlower ~~the~~bulk ~~U.S.~~shipments ~~for~~to ~~the~~international ~~three~~markets ~~months~~primarily ~~ended~~due ~~September~~to ~~30,~~delayed ~~2025~~product ~~when~~shipments ~~compared~~into tothe region impacted by the ~~same~~geopolitical ~~period~~conflicts indiscussed ~~2024~~above.

Sequentially, the ~~slight~~ decrease was due to the lower ~~level~~levels of ~~U.S.~~bulk ~~onshore~~sales ~~drilling~~in ~~and~~the ~~completion~~international ~~activity~~markets but ~~was~~partially ~~substantially~~ offset by ~~higher~~increased ~~levels~~product ofsales ~~bulk~~in ~~shipments~~the ~~to international markets~~U.S.

For the nine months ended September 30, 2025, product sales revenue was $95.8 million and decreased 7% compared to the same period in the prior year, primarily due to lower average U.S. onshore drilling and completion activity in 2025 compared to 2024, but was partially offset by an increase of laboratory instrument sales to international markets in 2025.

Cost of Services, excluding depreciation

Cost of services was $7476.91 million for the three months ended ~~September~~March 3031, ~~2025~~2026, aan ~~decrease~~increase of 14% year-over-year and ana ~~increase~~decrease of 15% sequentially. The year-over-year ~~decrease~~increase in cost of services was primarily due to ~~increased~~1) ~~efficiencies~~higher shipping and ~~the~~insurance ~~benefits of lower compensation~~ costs asresulting afrom ~~result of cost reduction initiatives implemented during~~ the ~~first~~geopolitical ~~half~~conflicts; ofand ~~2025.~~2) ~~Sequentially,~~an ~~the~~unfavorable ~~slight~~effect ~~increase in cost~~ of ~~services~~exchange isrates ~~primarily~~on ~~due~~costs todenominated ~~an increase~~ in ~~service~~foreign ~~revenue~~currency, ~~partially~~such ~~offset~~as by the ~~increased~~Euro ~~efficiencies~~ and ~~lower~~British ~~compensation~~Pound, ~~cost~~resulting asfrom ~~discussed~~the ~~above.~~devaluation ~~Cost~~ of ~~services expressed as a percentage of service revenue was 74% for~~ the ~~three~~U.S. ~~months~~dollar ~~ended~~during ~~September~~these 30periods, ~~2025,~~causing ~~compared~~higher toemployee ~~77%~~compensation ~~for the prior quarter~~ and ~~76%~~certain ~~for~~other ~~the~~operating ~~same~~costs ~~period~~ in ~~the~~some ~~prior~~international ~~year~~regions. ~~Cost of services as a percentage of service revenue improved primarily driven by the efficiencies and cost reduction initiatives as discussed above.~~

~~For~~Sequentially, the ~~nine~~decrease ~~months~~in ~~ended September 30, 2025,~~ cost of services ~~was~~is ~~$221.9~~primarily ~~million,~~due to a decrease ~~of 1% compared to the same period~~ in ~~the prior year. Cost of services expressed as a percentage of~~ service revenue ~~improved~~partially tooffset ~~76%~~by ~~from 77% when compared to~~ the ~~same~~increase ~~period~~ in ~~the~~employee ~~prior~~compensation ~~year. The year-over-year decrease in cost of services while service revenue remained relatively flat was primarily due to increased efficiencies~~ and ~~cost~~certain ~~reduction~~other ~~initiatives~~operating ascosts discussed above.

Cost of ~~Product~~services ~~Sales~~expressed as a percentage of service revenue was 81% for the three months ended March 31, ~~excluding~~2026, ~~depreciation~~compared to 77% for the same period in the prior year and 75% for the prior quarter and was primarily driven by lower revenue during the three months ended March 31, 2026 as client projects have been delayed or cancelled in the Middle East region as a result of the geopolitical conflict which escalated during the three months ended March 31, 2026. Although service revenue declined, the Company still incurred employee compensation and fixed overhead costs which increased cost of services as a percentage of service revenue. In addition, employee compensation and operating costs were higher due to changes in the exchange rates as discussed above.

Cost of product sales was $30.0 million for the three months ended September 30, 2025, a decrease of 4% year-over-year and an increase of 1% sequentially. Cost of product sales expressed as a percentage of product sales revenue was 90% for the three months ended September 30, 2025, compared to 88% for the same period in the prior year and compared to 87% in the prior quarter. The year-over-year changes in cost of product sales as a percentage of product sales increased primarily due to higher absorption of fixed costs on a lower revenue base that is partially associated with increased tariff cost on certain imported 24

Return to Index

~~materials,~~Cost ~~along with a write-down~~ of ~~certain~~Product ~~inventory of approximately $0.6 million in the three months ended September 30~~Sales, ~~2025.~~excluding depreciation

~~Sequentially,~~Cost ~~cost~~ of product sales aswas $26.0 million for the three months ended March 31, 2026, a ~~percentage~~decrease of ~~product~~2% ~~sales~~year-over-year ~~increased~~and ~~due~~11% tosequentially. ~~higher~~The ~~absorption~~year-over-year and sequential decrease in cost of ~~fixed~~product ~~costs~~sales onwere ain ~~lower~~line ~~revenue~~with ~~base~~changes in product sales revenue.

~~For the nine months ended September 30, 2025, cost of product sales was $86.2 million, a decrease of 4% compared to the same period in the prior year.~~ Cost of product sales expressed as a percentage of product sales revenue was 9094% for the ~~nine~~three months ended ~~September~~March 3031, ~~2025~~2026, compared to 8893% ~~from~~for the same period in the prior year. ~~The~~and ~~increase~~compared to 94% in the prior quarter. Changes in cost of product sales expressed as a percentage of product sales revenue ~~was~~year ~~due~~over toyear ~~higher~~was affected by absorption of fixed costs on achanges ~~lower~~in revenue base asand ~~discussed~~continued ~~above,~~increase ~~along~~in ~~with a write-down of~~ certain ~~inventory~~material ~~totaled~~and ~~$1.8~~logistic ~~million~~costs induring ~~2025, with no such write-down in~~ the ~~same~~three ~~period~~months inended ~~the~~March ~~prior~~31, ~~year~~2026.

General and Administrative Expense, excluding depreciation

General and administrative (“G&A”) expense includes corporate management and centralized administrative services that benefit our operations.

G&A expense for the three months ended ~~September~~March 3031, ~~2025~~2026, was $1014.7 million, which increased $21.0 million, compared to the same period in ~~2024~~2025. The year-over-year increase was primarily due to higher stock compensation expense recorded in ~~2025.~~2026 Inalong ~~2024, a portion of stock compensation expense that was previously recognized was reversed to align~~ with ~~the~~increased ~~expectations~~outside ofservice ~~vesting levels for certain performance share awards~~costs.

G&A expense for the three months ended ~~September~~March 3031, ~~2025~~2026, ~~was~~increased ~~comparable~~$4.1 million compared to the prior quarter ~~and~~primarily ~~increased~~due to the acceleration of stock compensation expense for retirement eligible executives of $03.27 million orin ~~less than 2%~~2026.

For the nine months ended September 30, 2025, G&A expense was $34.8 million which increased $4.1 million, compared to the nine months ended September 30, 2024. The year-over-year increase was primarily due to (1) a higher total stock compensation cost of $1.8 million; (2) a lower gain from mark-to-market adjustments on Company-owned life insurance policies of $1.3 million; and (3) increased license fees and implementation costs associated with a new global human capital management system.

Depreciation and Amortization Expense

Depreciation and amortization expense for the three months ended ~~September~~March 3031, ~~2025~~2026, was $3.68 million, aan ~~decrease~~increase of 21% year-over-year and ~~sequentially. Depreciation and amortization expense for the nine months ended September 30, 2025, was $11.0 million, a decrease of~~ 3% ~~year-over-year~~sequentially. The ~~decrease~~increase in depreciation and amortization expense compared to the prior year ~~periods~~period and sequentially is primarily due to ~~assets~~business ~~that~~acquisitions ~~had~~in ~~become fully depreciated~~2025.

Return to Index

Other (Income) Expense, Net

The components of other (income) expense, net, are as follows (in thousands):

	Three Months Ended						~~Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2025			2024			2025			2024
	2026			2025
(Gain) loss on sale of assets	$	(146	)	$	364		$	(369	)	$	(390	)
Gain on sale of assets	$	(1,013	)	$	(6	)
Results of non-consolidated subsidiaries		~~194~~79			(~~108~~37	)		~~401~~			~~(207~~	)
Foreign exchange (gain) loss, net		~~354~~380			~~(239~~480	)		~~841~~			~~435~~
Rents and royalties		(8—	)		(~~882~~7	)		~~(24~~	)		~~(1,683~~	)
Return on pension assets and other pension costs		(~~312~~350	)		(~~314~~280	)		~~(893~~	)		~~(891~~	)
Assets write-down, loss on lease abandonment and other exit costs		—			—			707			1,809
Assets write-down, loss on lease termination and other exit costs		639			707
Insurance recovery - business interruption and costs		(52	)		(1,151	)		(1,031	)		(3,481	)
Severance and other charges		—			2,256
Insurance recovery - property, plant and equipment		(5,253	)		(2,074	)		(6,830	)		(2,074	)
Other, net		(380	)		(778	)
Severance and other charges		—			—			2,256			824
Total other (income) expense, net	$	(645	)	$	2,335
Other, net		(367	)		(125	)		(1,280	)		(415	)
Total other (income) expense, net	$	(5,590	)	$	(4,529	)	$	(6,222	)	$	(6,073	)

During the ~~nine~~three months ended ~~September~~March 3031, ~~2025~~2026 and ~~2024~~2025, as a result of our continuous efforts in consolidating and exiting certain facilities in the U.S. and other international locations for operational efficiency, we sold property in Tulsa, Oklahoma for a net gain of $0.9 million. In addition, we recognized a write-down of the associated leasehold improvements, right of use assets and other assets and incurred lease abandonment and other exit costs of $0.76 million and $10.87 million, respectively.

Foreign exchange (gain) loss, net by currency is summarized in the following table (in thousands):

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2025			2024			2025			2024
British Pound	$	(48	)	$	(64	)	$	(108	)	$	6
Canadian Dollar		43			(13	)		(11	)		60
Colombian Peso		(38	)		44			(98	)		13
Euro		(30	)		201			772			266
Indonesian Rupiah		100			(332	)		133			(107	)
Russian Ruble		144			(4	)		(189	)		10
Swedish Krona		5			23			128			(7	)
Other currencies, net		178			(94	)		214			194
Foreign exchange (gain) loss, net	$	354		$	(239	)	$	841		$	435

Interest Expense

Interest expense for the three months ended September 30, 2025, was $2.7 million and decreased $0.5 million or 15% year-over-year and 2% compared to the prior quarter. For the nine months ended September 30, 2025, interest expense decreased $1.8 million or 18%.

The year-over-year and sequential decreases are primarily due to lower variable interest rates and average borrowings on our bank revolving credit facility during the three and nine months ended September 30, 2025.

Return to Index

Foreign exchange (gain) loss, net for the primary currencies in which we operate and those with a material effect for the period presented is summarized in the following table (in thousands):


	Three Months Ended
	March 31,
	2026			2025
British Pound	$	(64	)	$	(6	)
Canadian Dollar		23			46
Euro		(70	)		285
Indonesian Rupiah		50			74
Russian Ruble		97			(185	)
Other currencies, net		344			266
Foreign exchange (gain) loss, net	$	380		$	480

Interest Expense

Interest expense for the three months ended March 31, 2026, was $2.9 million and increased $0.3 million or 11% for both year-over-year and sequentially. The year-over-year and sequential increases are primarily due to borrowings of $50.0 million under the delayed draw term loan at higher variable interest rates used to repay the $45.0 million 2021 Senior Notes Series A at a lower fixed rate. Year over year, this was slightly offset by lower average borrowings and lower rates on our revolving credit facility.

Income Tax Expense (Benefit)

The Company recorded an income tax ~~expense~~benefit of $3(0.83) million ~~and $7.4 million~~ for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025,~~2026 ~~respectively~~ compared to income tax expense of $41.7 million ~~and $10.0 million~~ for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024, respectively~~2025. The effective tax rate for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025,~~2026 ~~was 20.5%~~ and ~~22.7%~~2025, ~~respectively. The effective tax rate for the three and nine months ended September 30, 2024,~~ was 2825.10% and 2896.82%, respectively. The effective tax rate for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~2026, was primarily impacted by the earnings mix of jurisdictions subject to tax for the period and ~~changes~~items ~~in uncertain tax position in certain jurisdictions which is~~ discrete to the quarter. The effective tax rate for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2024~~2025, was impacted by ~~the~~approximately ~~earnings~~$1.4 ~~mix~~million of ~~jurisdictions~~additional ~~subject~~tax toexpense ~~tax~~recorded for items discrete to the ~~period~~quarter. ~~and~~These discrete items ~~discrete~~are toprimarily associated with the ~~quarter~~finalization of certain tax jurisdictions’ return to provision assessments due to changes in estimates.

On July 4, 2025, the Act was enacted into law. The Act includes significant provisions, including tax cut extensions and modifications to the U.S. and international tax frameworks. We are evaluating the impact of these legislative changes as additional guidance becomes available, and uncertainty remains regarding the timing and interpretation by tax authorities in affected jurisdictions. These legislative changes could have an adverse impact on our future effective tax rate, tax assets and liabilities, including our deferred tax assets and liabilities, and cash payments for tax.

Segment Analysis

	Three Months Ended											Year-~~over~~Over-~~year~~Year	Sequential
	September 30, 2025				September 30, 2024			June 30, 2025				%Change	%Change
	March 31, 2026				March 31, 2025			December 31, 2025				% Change	% Change
REVENUE:
Reservoir Description	$	8881,~~224~~931		6667%	$	8880,~~840~~897	6665%	$	8692,~~280~~282		6667%	(1)%	2(11)%
Production Enhancement		4639,~~297~~866		3433%		4542,~~557~~688	3435%		4345,~~879~~973		3433%	2(7)%	6(13)%
Consolidated	$	~~134~~121,~~521~~797		100%	$	~~134~~123,~~397~~585	100%	$	~~130~~138,~~159~~255		100%	0(1)%	3(12)%
OPERATING INCOME:
Reservoir Description *	$	161,~~574~~146		191%	$	162,~~487~~339	193%	$	12,~~203~~823		14%	1(51)%	36(91)%
Production Enhancement *		~~4,379~~804		92%		31,~~232~~503	74%		3,~~148~~025		7%	35(47)%	39(73)%
Corporate and Other (1)		(2563	)	0%		84575	0%		(6016	)	0%	NM	NM
Consolidated	$	201,~~928~~887		162%	$	194,~~803~~417	154%	$	15,~~291~~832		1211%	6(57)%	37(88)%
* Percentage, which represents operating margins, is based on operating income divided by applicable revenue rather than total revenue."NM" means not meaningful(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.

	Nine Months Ended September 30,						Year-over-year
	2025			2024			% Change
REVENUE:
Reservoir Description	$	255,401	66%	$	259,353	66%	(2)%
Production Enhancement		132,864	34%		135,258	34%	(2)%
Consolidated	$	388,265	100%	$	394,611	100%	(2)%
OPERATING INCOME (LOSS):
Reservoir Description *	$	31,116	12%	$	34,823	13%	(11)%
Production Enhancement *		9,030	7%		9,209	7%	(2)%
Corporate and Other (1)		490	0%		350	0%	NM
Consolidated	$	40,636	10%	$	44,382	11%	(8)%
* Percentage, which represents operating margin, is based on operating income divided by applicable revenue rather than total revenue."NM" means not meaningful(1) "Corporate and Other" represents those items that are not directly related to a particular operating segment.

Return to Index

Reservoir Description

Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately 80% of its revenue sourced from existing producing fields, development projects and movement of crude oil products outside the U.S.

Revenue from the Reservoir Description operating segment of $8881.29 million for the three months ended ~~September~~March 3031, ~~2025~~2026 ~~decreased~~increased 1% year-over-year and ~~increased~~decreased 211% sequentially. ~~Revenue~~Year-over-year inrevenue ~~2025~~was ~~has~~slightly ~~been~~higher ~~negatively impacted by the decrease in the success rate~~ for ~~international~~reservoir ~~offshore~~rock ~~exploration~~ and ~~appraisal~~fluid ~~wells,~~analysis ~~which~~projects ~~reached~~in ~~a 20-year low for~~ the ~~six-month period ending March 31, 2025~~U.S. ~~The~~and ~~decrease~~laboratory incrude ~~international~~assay ~~offshore~~services ~~commercial success rates has resulted~~ in the ~~cancellation~~Europe ~~of several reservoir rock and fluid analysis projects that were originally planned for late 2024 and 2025~~region. However, ~~The~~sequentially, ~~slight~~the ~~decrease~~recent conflict in ~~year-over-year~~the ~~revenue~~Middle ~~was~~East, ~~primarily~~coupled ~~due~~with toongoing ~~lower~~geopolitical ~~revenue~~conflict in ~~reservoir~~Russia ~~rock~~ and ~~fluid~~Ukraine, ~~analysis~~and ~~projects in~~ the ~~U.S.~~expanded ~~but~~sanctions ~~was~~previously ~~substantially~~discussed, ~~offset~~further bydisrupted ~~higher~~client ~~revenue~~activity ~~from~~and ~~international~~demand ~~projects~~for ~~and~~our crude- assay ~~services.~~work ~~Sequentially,~~and ~~the~~regional ~~increase~~studies in ~~revenue~~certain ~~was~~international ~~primarily~~regions ~~due~~in tothe ~~higher~~three ~~revenue~~months inended ~~laboratory~~March ~~crude-assay~~31, ~~services~~2026.

~~Revenue~~Operating ~~from~~income of $1.1 million for the ~~Reservoir~~three ~~Description~~months ~~operating~~ended ~~segment~~March of31, 2026, decreased year-over-year by $~~255~~1.42 million and decreased $11.7 million sequentially. Operating margins were 1% for the ~~nine~~three months ended ~~September~~March 3031, ~~2025~~2026, ~~decreased~~compared 2to 3% ~~from~~for the same period in the prior year, and 14% sequentially. ~~The~~Year-over-year, ~~decreased~~despite a slight increase in revenue, the decrease in ~~2025~~operating isincome and operating margins was primarily ~~due~~attributable to ~~lower~~1) ~~revenue~~increases in ~~reservoir~~employee ~~rock~~compensation and ~~fluid~~operating ~~analysis~~costs caused by unfavorable effects of exchange rates discussed above; and 2) a higher level of Corporate G&A expenses of $0.7 million absorbed in the Usegment.~~S.,~~ asSee ~~discussed~~discussion of General and Administrative Expense, above. ~~The~~These ~~decrease~~cost isincreases were partially offset by ~~higher~~lower ~~revenue~~facility inexit ~~international~~costs ~~laboratory~~and ~~crude~~certain asset write-~~assay~~downs ~~services~~totaling $0.6 million recorded during the three months ended March 31, 2026 compared to a total charge of $2.7 million on severance, facility exit costs and ~~higher~~asset ~~laboratory~~write-downs ~~instrument~~recorded ~~sales~~for inthe three months ended March 31, 2025.

~~Operating~~Sequentially, ~~income~~the ofdecrease ~~$16.6~~in ~~million~~operating ~~for~~income ~~the~~and ~~three~~operating ~~months~~margins ~~ended~~was ~~September~~primarily ~~30,~~due ~~2025,~~to ~~was~~1) ~~relatively~~a ~~flat~~decrease ~~year-over-year~~in ~~and~~revenue ~~increased~~of $410.4 million ~~sequentially.~~in ~~Operating margins were 19% for~~ the three months ended ~~September~~March 3031, ~~2025,~~2026; ~~comparable~~2) ~~for~~a ~~the~~total ~~same~~charge ~~period~~of ~~in the prior year, and 14% sequentially~~$0.6 ~~Year-over-year,~~million ~~the changes in operating income and operating margins was primarily attributable to gains on insurance recovery~~ associated with ~~the~~facility ~~fire~~exit atcosts ~~the~~and ~~Aberdeen,~~certain ~~U.K.~~asset ~~facility~~write-downs ~~of $5.3 million~~ recorded induring the three months ended ~~September~~March 3031, ~~2025,~~2026 ~~compared~~and tono asuch ~~$3.2~~costs ~~million~~recorded ~~gain~~ in ~~the same period in~~ prior ~~year.~~quarter; ~~The~~and ~~additional~~3) ~~gain~~a onhigher ~~insurance~~level ~~recovery~~of ~~was~~Corporate ~~substantially~~G&A ~~offset~~expenses byof a$3.3 ~~different~~million ~~mix~~absorbed ofin ~~revenue~~the ~~with~~segment. aSee ~~higher~~discussion ~~level~~ of ~~laboratory~~General ~~instrument~~and ~~sales~~Administrative ~~in 2025~~Expense, ~~which yield a lower margin~~above.

Sequentially, the increase in operating income and operating margins was primarily due to 1) incremental revenue of $2.0 million in the three months ended September 30, 2025; and 2) insurance recovery associated with the fire at the Aberdeen, U.K. facility of $5.3 million recorded in the three months ended September 30, 2025, compared to a $2.6 million recorded in the prior quarter.

Operating income of $31.1 million for the nine months ended September 30, 2025, decreased $3.7 million from the same period in the prior year. Operating margins were 12% for the nine months ended September 30, 2025, compared to 13% for the same period in the prior year. The decrease in operating income and operating margins was primarily attributable to 1) a lower level of revenue in 2025; 2) a different mix of revenue with a higher level of laboratory instrument sales that yield lower margin compared to service revenue; and 3) a total charge of $2.7 million associated with employee severance, facility consolidation and asset write-down recorded in 2025 compared to $1.5 million recorded in the same period in prior year. The decrease in operating income and operating margins was partially offset by a higher insurance recovery associated with the fire at the Aberdeen, U.K. facility in the nine months ended September 30, 2025, compared to the same period in prior year.

Production Enhancement

Production Enhancement operations are largely focused on complex completions in unconventional oil and gas reservoirs in the U.S. as well as conventional projects across the globe. U.S. onshore drilling and completion activities typically experience a seasonal decline at end of the year with activity levels increasing at the beginning of the year. Average rig count in the U.S. land market for the three months ended ~~September~~March 3031, ~~2025~~2026, was down by 7% year-over-year ~~and~~but 6%was relatively flat sequentially. International rig count was down 61% year-over-year ~~and~~but ~~relatively~~increased ~~flat~~by 2% sequentially.

Revenue from the Production Enhancement operating segment of $39.9 million for the three months ended March 31, 2026, decreased 7% year-over-year and 13% sequentially. Year-over-year, the decrease was primarily due to lower product sales due to the decline in bulk shipments in the international market, while the U.S. land market was relatively flat. Sequentially, the decrease was primarily driven by a decrease in large customer bulk shipment orders in the international markets, as well as a decrease in US land market activity.

Operating income of $0.8 million for the three months ended March 31, 2026, decreased $0.7 million year-over-year, and decreased $2.2 million sequentially. Operating margins for the three months ended March 31, 2026, were 2%, compared to operating margins of 4% year-over-year and 7% sequentially. Year-over-year, the decrease in operating income and margins was primarily due to 1) a decrease in revenue of $2.8 million; and 2) continued increase in certain material and logistic costs during the three months ended March 31, 2026.

Return to Index

~~Revenue~~Sequentially, ~~from~~ the ~~Production~~decrease ~~Enhancement~~in operating ~~segment~~income ~~of $46.3 million for the three months ended September 30, 2025, increased 2% year-over-year~~ and 6%margins ~~sequentially. Year-over-year, the increase~~ was primarily driven by 1) a ~~strong~~decrease ~~growth~~ in ~~well~~revenue ~~completion~~of ~~diagnostic~~$6.1 ~~services~~million infor the ~~U.S.~~reasons ~~and~~discussed ~~international~~above; ~~markets.~~2) ~~Sequentially,~~increased ~~the~~materials ~~increase~~and ~~was~~operational ~~primarily~~cost ~~driven~~discussed byabove; ~~increased~~and ~~product~~3) ~~sales~~a inhigher ~~bulk~~level ~~shipment~~of inCorporate ~~the~~G&A ~~international~~expenses ~~markets,~~of ~~and~~$1.5 ~~continued~~million ~~growth~~absorbed in ~~well~~the ~~completion~~segment. ~~diagnostic~~See ~~services~~discussion ~~for~~of ~~projects~~General inand ~~the~~Administrative ~~Gulf~~Expense, ~~of Mexico~~above.

Revenue from the Production Enhancement operating segment of $132.9 million for the nine months ended September 30, 2025, decreased 2% from the same period in the prior year. The decrease in revenue is primarily due to lower product sales in the U.S. land market in 2025, partially offset by higher revenue in well completion diagnostic services in the U.S. and international markets.

Operating income of $4.4 million for the three months ended September 30, 2025, increased $1.1 million year-over-year, and increased $1.2 million sequentially. Operating margins for the three months ended September 30, 2025, were 9%, compared to operating margins of 7% year-over-year and sequentially. Year-over-year, the increase in operating income and margins was primarily driven by a different mix of revenue with higher well completion diagnostic service revenue that yields a higher margin. Sequentially, the increase in operating income and margins was primarily driven by incremental revenue of $2.4 million in the three months ended September 30, 2025.

Operating income of $9.0 million for the nine months ended September 30, 2025, decreased $0.2 million compared to the same period in the prior year. Operating margins for the nine months ended September 30, 2025 of 7% were comparable to the same period of the prior year. The slight decrease in operating income and margins was primarily due to a higher absorption of fixed costs on lower product sales that is partially associated with increased tariff cost on certain imported materials, substantially offset by higher margin yield from well completion diagnostic service revenue as discussed above.

Liquidity and Capital Resources

General

We have historically financed our activities through cash on hand, cash flows from operations, bank credit facilities, equity financing and the issuance of debt. Cash flows from operating activities provide the primary source of funds to finance operating needs, capital expenditures, dividends and ~~our~~discretionary share ~~repurchase program~~repurchases. Our ability to maintain and grow our operating income and cash flow depends, to a large extent, on continued investing activities. We believe our future cash flows from operations, supplemented by our borrowing capacity and the ability to issue additional equity and debt, should be sufficient to fund our debt requirements, capital expenditures, working capital, dividends, discretionary share ~~repurchase~~repurchases ~~program~~ and future acquisitions. The Company will continue to monitor and evaluate the availability of capital in the debt and equity markets.

We are a holding company incorporated in Delaware. ~~Therefore,~~and we conduct substantially all of our operations through our subsidiaries. Our cash availability is largely dependent upon the ability of our subsidiaries to pay cash dividends or otherwise distribute or advance funds to us and on the terms and conditions of our existing and future credit arrangements. There are no restrictions preventing any of our subsidiaries from repatriating earnings, except for the unrepatriated earnings of our Russian subsidiary which are not expected to be distributed in the foreseeable future, and there are no restrictions or income taxes associated with distributing cash to the parent company through loans or advances. ~~As of September 30, 2025, $22.2 million of our $25.6 million of cash was held by our foreign subsidiaries.~~

The Company maintains the quarterly dividend of $0.01 per share.

Cash Flows

~~The~~As ~~following~~of ~~table~~March ~~summarizes~~31, 2026, we had $22.8 million of cash ~~flows~~and ~~(in~~cash ~~thousands):~~equivalents, compared to $22.7 million of cash and cash equivalents at December 31, 2025. As of March 31, 2026, $22.1 million of our $22.8 million of cash was held by our foreign subsidiaries.

32Cash flows from operating activities were $4.0 million for the three months ended March 31, 2026. The decrease compared to the same period in the prior year was primarily due to lower operating activity and higher operating costs, as discussed above.

Other sources of cash during the three months ended March 31, 2026 include receipt of $1.2 million from the sale of property in Tulsa, Oklahoma. See “Credit Facility, Senior Notes and Available Future Liquidity” below regarding a net increase in our debt of $4.0 million.

Uses of cash during the three months ended March 31, 2026 include: 1) total capital expenditures of $4.9 million, which includes $1.4 million related to the replacement of assets damaged in the Aberdeen, U.K. fire incident which have been covered by insurance proceeds; 2) share repurchases of $4.0 million, which includes payments related to personal tax liabilities of participants in our stock-based compensation plan; and 3) quarterly dividend paid of $0.5 million.

We utilize the non-GAAP financial measure of free cash flow to evaluate our cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures. Management believes that free cash flow provides useful information to investors regarding the cash available in the period that was in excess of our needs to fund our capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income (loss) or cash flows from operating, investing or financing activities, each as determined in accordance with GAAP. Free cash flow does not represent residual cash available for distribution because we may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a

Return to Index

	Nine Months Ended September 30,
	2025			2024			% Change
Cash flows provided by (used in):
Operating activities	$	29,085		$	35,773		(19)%
Investing activities		1,521			(2,835	)	NM
Financing activities		(24,134	)		(26,584	)	(9)%
Net change in cash and cash equivalents	$	6,472		$	6,354		2%

measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented, may not be comparable to similarly titled measures presented by other companies. The following table reconciles this non-GAAP financial measure to the most directly comparable measure calculated and presented in accordance with GAAP (in thousands):

Comparing the nine months ended September 30, 2025 to the same period in the prior year, cash flows provided by operating activities decreased to $29.1 million in 2025 compared to $35.8 million in 2024. Net income for the nine months ended September 30, 2025 includes gain on insurance proceeds associated with assets of $6.8 million compared to $2.1 million in the same period in the prior year. Additionally, cash from operating activities was impacted by a decrease in working capital in 2025 compared to the same period in the prior year.


	Three Months Ended March 31,
	2026			2025
Free cash flow calculation:
Net cash provided by operating activities	$	3,965		$	6,660
Less: Cash paid for capital expenditures - operations		(3,448	)		(2,785	)
Free cash flow	$	517		$	3,875

~~Cash~~Free ~~flows~~cash ~~provided~~flow ~~by investing activities~~ for the ~~nine~~three months ended ~~September~~March 3031, ~~2025~~2026 ofwas $10.5 million ~~include~~compared ~~proceeds~~to ~~on the sale of assets of~~ $23.49 million, ~~proceeds~~for ~~from~~the ~~insurance~~same ~~recovery~~period ~~associated~~in ~~with~~2025. ~~the~~The ~~fire~~net ~~incident~~cash atprovided ~~the~~by ~~Aberdeen,~~operating ~~U.K.~~activities ~~facility~~ of $104.0 million, ~~and~~during ~~proceeds~~the onthree ~~company~~months ~~owned~~ended ~~life~~March ~~insurance policies of $0.8 million~~31, ~~offset~~2026 bycompared ~~total~~to ~~capital expenditures of~~ $106.97 million ~~and~~for athe ~~business~~same ~~acquisition,~~period ~~net~~in of2025 ~~cash~~was ~~acquired~~primarily ofdue ~~$0.6~~to ~~million.~~the ~~Cash~~factors ~~flows~~as ~~used~~discussed in ~~investing~~cash ~~activities~~flow ~~for~~from ~~the~~operating ~~nine~~activities ~~months~~above. ~~ended~~Capital ~~September 30~~expenditures-operations, ~~2024~~which ofexclude ~~$2.8~~capital ~~million~~expenditures ~~include the funding~~ of $81.64 million ~~for~~associated ~~capital~~with ~~expenditures~~the Aberdeen, ~~partially~~U.K. ~~offset~~fire byincident ~~$2.1~~that ~~million~~are ofcovered ~~proceeds~~by ~~from~~ insurance, ~~recovery~~increased ~~associated~~by ~~with the 2024 fire incident,~~ $0.97 million ofduring ~~proceeds from~~ the ~~sale~~three ofmonths ~~assets~~ended ~~and~~March ~~$2.8~~31, ~~million~~2026 ofcompared ~~net~~to ~~proceeds~~the ~~received~~same ~~from~~period ~~company~~in ~~owned~~the ~~life~~prior ~~insurance policies~~year.

Cash flows used in financing activities for the nine months ended September 30, 2025 of $24.1 million include an $11.0 million net reduction in long-term debt, $1.7 million of debt issuance costs associated with the renewal of our credit facility, $1.4 million for quarterly dividends, and $9.8 million used to repurchase the Company’s common stock. Cash flows used in financing activities for the nine months ended September 30, 2024 of $26.6 million include a $24.0 million net reduction in long-term debt, $1.4 million for quarterly dividends, $0.4 million used to repurchase the Company’s common stock and $0.8 million in costs associated with equity transactions.

During the nine months ended September 30, 2025, we repurchased 831,478 shares of our common stock for $9.8 million, including rights to 16,915 shares of our common stock to satisfy personal tax liabilities of participants in our stock-based compensation plan for an aggregate purchase price of $211 thousand.

Return to Index

	Nine Months Ended September 30,
	2025			2024			% Change
Free cash flow calculation:
Net cash provided by operating activities	$	29,085		$	35,773		(19)%
Less: Cash paid for capital expenditures - operations		(8,265	)		(8,647	)	(4)%
Free cash flow	$	20,820		$	27,126		(23)%

Free cash flow for the nine months ended September 30, 2025, decreased $6.3 million from $27.1 million for the same period in 2024. The net cash provided by operating activities of $29.1 million during the nine months ended September 30, 2025, decreased $6.7 million primarily due to the factors as discussed in the cash flow from operating activities above. Capital expenditures-operations, which exclude capital expenditures of $2.7 million associated with the Aberdeen, U.K. fire incident and are covered by insurance, decreased slightly by $0.4 million during the nine months ended September 30, 2025 compared to the same period in the prior year.

Credit Facility, Senior Notes and Available Future Liquidity

We, along with our direct subsidiary Core Laboratories (U.S.) Interests Holdings, Inc. (“CLIH”), have a secured ~~the~~credit ~~Credit~~facility ~~Facility~~ for an aggregate borrowing commitment of $150.0 million with a $50.0 million “accordion” feature (“Credit Facility”). Draws up to $100.0 million are available in the form of a revolving credit facility, and a single draw of $50.0 million was made in the form of a delayed draw term loan on January 12, 2026. The $50.0 million proceeds from the delayed draw term loan were primarily used to retire $45 million of the senior notes which matured on January 12, 2026, as discussed below. As of ~~September~~March 3031, ~~2025~~2026, the Credit Facility has an available borrowing capacity of approximately $~~131~~85.95 million.

~~See~~Additionally, ~~Note~~we 7along –with ~~Long-term~~CLIH ~~debt~~as issuer, ~~net~~have ofsenior notes outstanding that were issued through private placement transactions (“Senior Notes”). On January 12, 2026, we repaid the 2021 Senior Notes toSeries A with aggregate principal amount of $45.0 million upon the ~~Interim~~maturity ~~Consolidated~~date ~~Financial~~with ~~Statements,~~the ~~for~~single ~~additional~~draw ~~information~~of ~~regarding~~$50.0 million from the ~~Credit~~delayed ~~Facility~~draw term loan.

Additionally, we along with CLIH as issuer, have senior notes outstanding that were issued through private placement transactions.

These debt instruments are summarized in the following table (in thousands):

	Interest Rate	Maturity Date	~~September~~March 3031,~~2025~~2026			December 31,~~2024~~2025
Credit Facility			$	7,000		$	18,000
Credit Facility - Revolving Loan	Variable	July 22, 2029	$	2,000		$	3,000
2021 Senior Notes Series A (1)	4.09%	January 12, 2026		45,000			45,000
Credit Facility - Delayed Draw Term Loan	Variable	July 22, 2029		50,000			—
2021 Senior Notes Series A (1)	4.09%	January 12, 2026		—			45,000
2021 Senior Notes Series B (1)	4.38%	January 12, 2028		15,000			15,000
2023 Senior Notes Series A (2)	7.25%	June 28, 2028		25,000			25,000
2023 Senior Notes Series B (2)	7.50%	June 28, 2030		25,000			25,000
Total long-term debt				117,000			~~128~~113,000
Less: Debt issuance costs				(2,~~897~~540	)		(12,~~889~~745	)
Long-term debt, net			$	114,~~103~~460		$	~~126~~110,~~111~~255

(1) Interest is payable semi-annually on June 30 and December 30.

(2) Interest is payable semi-annually on March 28 and September 28.

In accordance with the terms of the Credit Facility, our leverage ratio is 1.10, and our interest coverage ratio is 7.86, each for the period ended September 30, 2025. We are in compliance with all covenants contained in our Credit Facility and Senior Notes as of September 30, 2025. Certain of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes. See Note 76 - Long-term Debt, net of the Notes to the Interim Consolidated Financial Statements for additional information regarding the terms and financial covenants of the Credit Facility and the Senior Notes.

See Note 11 - Derivative Instruments and Hedging Activities of the Notes to the Interim Consolidated Financial Statements, for additional information regarding interest rate swap agreements we have entered to fix the underlying risk-free rate on our Credit Facility and the 2023 Senior Notes.29

Return to Index

In accordance with the terms of the Credit Facility, our leverage ratio is 1.20, and our interest coverage ratio is 7.20, each for the period ended March 31, 2026. We are in compliance with all covenants contained in our Credit Facility and Senior Notes as of March 31, 2026. Certain of our material, wholly owned subsidiaries are guarantors or co-borrowers under the Credit Facility and Senior Notes.

See Note 10 - Derivative Instruments and Hedging Activities of the Notes to the Interim Consolidated Financial Statements, for additional information regarding interest rate swap agreements we have entered to fix the underlying risk-free rate on our 2023 Senior Notes Series A and B.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in market risk from the information provided in Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” of Core Laboratories Inc.'s Annual Report on Form 10-K for the year ended December 31, ~~2024~~2025.

Item 4. Controls and Procedures

A complete discussion of our controls and procedures is included in Core Laboratories Inc.'s Annual Report on Form 10-K for the year ended December 31, ~~2024~~2025.

Disclosure Controls and Procedures

Our management, under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this report. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of ~~September~~March 3031, ~~2025~~2026, at the reasonable assurance level.

Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. Further, the design of disclosure controls and internal control over financial reporting must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There have been no changes in our system of internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the fiscal quarter ended ~~September~~March 3031, ~~2025~~2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Return to Index

CORE LABORATORIES INC.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

See Note 98 - Commitments and Contingencies of the Notes to the Interim Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report.

Item 1A. Risk Factors

Our business faces many risks. Any of the risks discussed in this Quarterly Report or our other SEC filings could have a material impact on our business, financial position or results of operations.

Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also impair our business operations. For a detailed discussion of the risk factors that should be understood by any investor contemplating investment in our securities, please refer to “Item 1A - Risk Factors” in Core Laboratories Inc.’s Annual Report on Form 10-K for the year ended December 31, 2025.

Return to Index

for the year ended December 31, 2024. In addition to the risk factors identified in our 2024 Annual Report, we updated the following risk factor:

Tariffs and other trade measures could adversely affect our business, results of operations, financial position and cash flows.

Our business and results of operations may be adversely affected by uncertainty and changes in U.S. trade policies, including tariffs, trade agreements or other trade restrictions imposed by the U.S. or other governments. Our input costs for raw materials and other goods, such as steel, electronic components, chemical reagents and laboratory equipment, are adversely affected by tariffs imposed by the U.S. government on products imported into the United States. Additionally, we sell our products internationally and our product sales may be subject to any retaliatory measures by other countries. Any imposition of or increase in tariffs on the goods we purchase or the products we sell could increase our costs and the price of our products and services. To the extent we are unable to pass all or a portion of these cost increases on to our customers, such cost increases could adversely affect our results of operations.

Additional tariffs, further trade restrictions and retaliatory trade measures could disrupt our supply chain and logistics, restrict or limit the availability of goods or supplies, cause adverse financial impacts due to volatility in foreign exchange rates and interest rates, and inflationary pressures on raw materials. It may be time-consuming and expensive for us to alter our business operations to adapt to or comply with any changes in international trade policies and agreements and any failure to do so could have a material adverse effect on our business. Any potential impact will depend on future developments with respect to trade policy and the results of trade negotiations, all of which are beyond our control. These potential impacts, while uncertain, could adversely affect our business, results of operations and financial condition.

Tariffs or other trade restrictions may lead to continuing uncertainty and volatility in U.S. and global financial and economic conditions and commodity markets, declining consumer confidence, significant inflation and diminished expectations for the economy, and ultimately reduced demand for our products and services and the demand for crude oil and gas. Such conditions could have a material adverse impact on our business, results of operations and cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Issuer Purchases of Equity Securities

The following table provides information about our purchases of shares of our common stock, par value $0.01, that are registered by us pursuant to Section 12 of the Exchange Act during the three months ended ~~September~~March 3031, ~~2025~~2026:

Period	Total Number of SharesPurchased (1)		Average PricePaid PerShare		Total Number of SharesPurchased as Part of aPublicly AnnouncedProgram (2)		Maximum Number ofShares That May Yet bePurchased Under theProgram (2)
July 1-31, 2025		172,070	$	11.45		—		—
January 1-31,2026		—	$	—		—		—
August 1-31, 2025		275,030	$	10.38		—		—
February 1-28, 2026		50,216	$	18.08		—		—
September 1-30, 2025		15,148	$	12.16		—		—
March 1-31, 2026		1,565	$	17.59		—		—
Total		~~462~~51,~~248~~781	$	1018.8406		—

(1)

During the three months ended ~~September~~March 3031, ~~2025~~2026, 4we repurchased 50,~~461~~086 shares in the open market. Additionally, 1,695 shares were surrendered to us by participants in a stock-based compensation plan to settle any personal tax liabilities which may result from the award. ~~Additionally,~~The werepurchase ~~purchased~~of ~~457,787~~ shares in the open market. ~~Repurchases~~is ~~of common stock are~~ at the discretion of ~~the~~our ~~board~~Board of ~~directors~~Directors and management.

(2)

36The Company does not have a publicly announced share repurchase program; however, it does from time to time undertake share repurchases in the open market at the discretion of Company management and with prior authorization from the Board of Directors.

Return to Index

The Company does not have a formal share repurchase program; however, it does from time to time undertake share repurchases in the open market at the discretion of Company management and with prior authorization from the Board of Directors.

Item 5. Other Information

During the three months ended ~~September~~March 3031, ~~2025~~2026, no director or officer of the Company adopted, modified or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” within the meaning of Item 408(a) of Item 408 of Regulation S-K.

3731

Return to Index

Item 6. Exhibits

ExhibitNo.		Exhibit Title	Incorporated byreference from thefollowing documents
10.1	-	Core Laboratories Inc. Nonqualified Deferred Compensation Plan for Board of Directors	Filed herewith
3.1		First Amended and Restated Bylaws	Form 8-K, March 5, 2026
10.2	-	Ninth Amended and Restated Credit Agreement, dated July 22, 2025, by and among, Core Laboratories Inc. and Core Laboratories (U.S.) Interests Holdings, Inc., as borrowers, Bank of America, N.A., as administrative agent and the other lenders party hereto	Form 8-K, July 23, 2025 (File No. 001-41695)
31.1	-	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
31.2	-	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.1	-	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
32.2	-	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
101.INS	-	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document	Filed herewith
101.SCH	-	Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents	Filed herewith
104	-	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)	Filed herewith

3832

Return to Index

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, Core Laboratories Inc., has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		CORE LABORATORIES INC.
Date:	~~October~~April 2330, ~~2025~~2026	By:	/s/ Christopher S. Hill
			Christopher S. Hill
			Chief Financial Officer
			(Duly Authorized Officer and
			Principal Financial Officer)

3933

Return to Index

Filing Compare · Core Laboratories Inc. /DE/